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ABSTRACT

The Effect of a Voice Treatment on Facial Expression in Parkinson’s Disease: Clinical and
Demographic Predictors
by
Amanda D. Bono

Advisor: Joan C. Borod

Parkinson’s disease (PD) is a neurodegenerative disease associated with a wide range of
motoric, cognitive, and behavioral symptoms. Impairments in facial mobility and emotional
expressivity are common and can impair communication, in turn, affecting daily functioning and
quality of life. Previous research suggests that the Lee Silverman Voice Treatment © (LSVT
LOUD; Ramig et al., 2001, 2011) increases vocal loudness and facial expressivity in individuals
with PD compared to PD and healthy controls. This study extends the literature by examining the
effects of LSVT and an articulation-based control treatment (i.e., ARTIC) on multiple aspects of
facial expressivity (i.e., emotional frequency [EF], emotional variability [EV], emotional
intensity [EI], and social engagement [SE]) as well as non-emotional facial mobility (FM).
Further, we examined whether demographic, clinical, cognitive, and affective variables predict
facial expressivity and mobility improvement via LSVT.
Participants included 40 individuals with idiopathic PD (67.5% male) and 14
demographically-matched healthy controls (60% male). The PD participants were randomly
assigned to one of the following conditions: the LSVT LOUD treatment group (n = 13), a control
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therapy (Articulation Treatment [ARTIC]; n = 14), or an Untreated Control Condition (n = 13).
All posers (PDs & HCs) were video-taped, before and after treatment (for the LSVT & ARTIC
PD groups) or at baseline and after a 4-5 week waiting period for (for the Untreated PDs [UPDs]
& HCs), while producing emotional (Happy, Sad, & Angry) monologues from the New York
Emotion Battery (Borod et al., 1998; Borod, Welkowitz, & Obler, 1992). The monologues were
randomized and divided into 15-second segments, and evaluated by 18 naïve raters for 4
different aspects of facial emotional expression and facial mobility. Separate training sessions
were held for each of the five facial rating variables (i.e., FM, EF, EV, EI, & SE), and interrater
reliability was largely in the high range.
Findings revealed that PD posers displayed lower facial expressivity than HCs on three
out of five variables, however, these effects were moderated by gender and emotion. In terms of
gender, women were more expressive than men on all facial expression variables. Treatment
results showed that individuals in the LSVT group showed significant improvements from preto post-treatment in facial expressivity for four out of the five variables examined (i.e., FM, EF,
EV, & EI), however, for EV, this interaction was moderated by Gender, with significant
increases from pre- to post-treatment for men but not for women in the LSVT group. There were
no significant differences observed pre- to post-treatment for ARTIC or from baseline to 4-5
weeks later for the UPD and HC groups. In terms of predictive findings, demographic, clinical,
cognitive, and affective variables did not predict facial improvement in LSVT participants, likely
due to low power.
This study has multiple clinical and research implications. First, we examined facial
expression through a multifactorial approach, involving mobility, expressivity, and social
judgment of others, which has not been done in other studies with PD and which may provide a
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better understanding of the specific facial impairments in PD. Clinically, our treatment findings
for LSVT are important to the rehabilitation therapy literature, because there are very few
empirically-validated treatments targeting facial emotional expressivity and facial mobility in
individuals with PD.
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Introduction
The Role of Emotional Processing in Daily Functioning
Emotion communication occurs through multiple channels, including facial,
prosodic/intonational, postural, gestural, and lexical (i.e., speech content) expression (Borod,
1993b). Although most emotions are expressed simultaneously through several channels, facial
expression is considered to be one of the most important channels for emotional communication
(Assuras, Barry, Borod, Halfacre, & Crider, 2005; Borod & Koff, 1984). Effective emotional
communication and social interaction play a vital role in one’s ability to operate within human
society (Dowding, Shenton, & Salek, 2006), affecting quality of life (Behari, Srivastava, &
Pandey, 2005; McKinley et al., 2008; Schrag, 2006; Slawek, Derejko, & Lass, 2005). Of note,
Charles Darwin theorized that facial emotional expression has adaptive value and is critical for
the survival of the human species (Darwin, 1859).
Facial expression of emotion is an important aspect of the emotional processing
framework. Evidence from decades of emotion research supports the existence of universal
discrete facial emotional expressions (e.g., happiness, sadness, anger, disgust, fear, and surprise)
that are produced and recognized across cultures (Ekman, 1992; Izard, 1994; Russell, 1994;
Walbott & Scherer, 1986). According to Borod (1993b), there are four components of emotion
processing; these include the channel of communication (e.g., facial, prosodic/intonational,
lexical [i.e., verbal content], gestural, and postural), modes of processing (e.g., expression,
perception, experience, and physiological arousal), discrete emotions (e.g., happiness, sadness,
anger, disgust, fear, and surprise), and emotional dimensions (e.g., pleasant/unpleasant and
approach/withdrawal). Emotion expression denotes the production and communication of an
emotion whereas emotion perception is defined as the ability to discern and interpret the
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emotional expressions of other individuals. Previous studies have revealed multiple differences
between expression and perception in healthy (e.g., Fridlund, Ekman, & Oster, 1987) and braindamaged populations (e.g., Borod, Koff, Lorch, & Nicholas, 1986). Additionally, there are
documented dissociations between emotional expression and experience (Borod et al., 2008).
These differences among the above constructs (e.g., expression, perception, and experience)
demonstrate that emotional processing variables are discrete constructs, thereby allowing
researchers to examine emotional processing modes independently. Other evidence to support
the theory that expression, perception, and experience are discrete entities includes the finding
that impairment in one area of emotional processing may occur despite intact functioning in
another mode. For instance, evidence suggests that individuals with Parkinson’s disease display
deficits in facial expressivity although they report experiencing emotions with the same intensity
as healthy controls (Borod et al., 2008; for reviews, see Borod & Brickman, 2001; McCabe,
Borod, Meltzer, Spielman, & Ramig, 2010; Zgaljardic, Borod, Foldi, & Mattis, 2003).
Symptoms in Parkinson’s Disease
Epidemiology and symptomatology. PD is the second most common neurodegenerative
disease in the world (de Lau & Breteler, 2006), and it affects approximately 1-2% of the
population over 65 years of age and 3-5% of the population 85 years of age and over (Fahn,
2003). It is estimated that six to eight million individuals over the age of 65 are currently living
with PD around the world (Sapir, Ramig, & Fox, 2008), with over one million of the cases
reported in the United States (Kandel, Schwartz, & Jessell, 2000). These figures are expected to
increase, as the number of individuals with PD over age 50 in the top 10 most populated Western
countries is projected to double by 2030 (Dorsey et al., 2007). PD poses a significant burden on
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the economy and healthcare system in the US, costing about $26 billion each year (Dodel et al.,
1998), underscoring the need for reliable, effective, and efficient treatment.
Motor symptoms and neural mechanisms. Parkinson’s disease (PD) was originally
described by James Parkinson (1817) as the “Shaking Palsy.” Today, it is conceptualized as a
progressive neurodegenerative disorder characterized by spontaneous motor impairments due to
the reduction of dopaminergic neurons in the substantia nigra pars compacta (SNc) of the basal
ganglia (e.g., Jankovic, 2008). Characterisitc motor impairments in PD include akinesia,
bradykinesia, resting tremors, motor rigidity, postural instability, hypokinetic dysarthria, and
masked facies (for reviews, see Jankovic, 2008; Ramig, Fox, & Sapir, 2008). Akinesia refers to
difficulty initiating motor movements, resulting in the reduction of spontaneous, voluntary
movements, whereas brakykinesia denotes reduced amplitude and speed of motor movement
(Kandel et al., 2000). Resting tremors are typically unilateral, prominent in the distal part of an
extremity (e.g., hands), and typically occur at a frequency between 4 and 6 Hz (Jankovic et al.,
2008). Motor rigidity is characterized by increased muscular resistance to passive guided
movement in proximal (e.g., neck, shoulders, and hips) or distal (e.g., wrists and ankles) limbs
and is usually accompanied by an underlying tremor. Rigidity is reported by patients to be very
painful and is typically one of the initial symptoms of PD, commonly misdiagnosed as arthritis
(Stamey, 2007). Postural instability usually appears later in the disease and frequently causes
impaired balance and unsteady or magnetic gait (Blumenfeld, 2002). According to imaging
studies, a possible mechanism for the motor deficits frequently seen in individuals with PD is the
severe reduction of dopamine in the caudal putamen, an area of the striatum that is associated
with the cortico-basal ganglia-thalamo-cortical motor circuit (Brooks, 2000). Additional
evidence suggests that the dopamine loss in PD is often widespread, affecting multiple

3

subcortical structures, including the subthalamic nucleus of thalamus (STN), the globus pallidus
internal segment (GPi), striatum, and the substantia nigra pars reticulate (SNr), in addition to
cortical areas (Kandel, Schwartz, Jessell, Siegelbaum, & Hudspeth, 2012). The impact of
dopamine reduction on cortical areas may explain the non-motor symptoms of PD (i.e.,
symptoms involving mood and cognition).
Non-motor symptoms. In addition to the classical motor symptoms experienced by
individuals with PD, many cognitive and behavioral deficits have been documented. The
cognitive sequalae of PD include deficits in processing speed, attention (especially divided
attention), episodic memory, and executive functioning (e.g., working memory, problem-solving,
set-shifting, planning, organization, and inhibition tasks; Zgaljardic, Borod, Foldi, & Mattis,
2003; Zgaljardic et al., 2006). Changes in mood and behavior frequently include symptoms of
depression (experienced by 40-70% of individuals with PD), apathy (16-50%), anxiety
(approximately 40%), hallucinations (approximately 30%), fatigue (approximately 40%), and
sleep-related issues (approximately 80%; for reviews, see Frisina, Borod, Foldi, & Tenenbaum,
2008; McKinley et al., 2008; Raskin, Borod, & Tweedy, 1990; Zgaljardic, Foldi, & Borod, 2004;
Zgaljardic et al., 2007). These cognitive and mood symptoms are displayed by the majority of
PD patients (over 77%; McKinley et al., 2009) and have been found to affect quality of life
(Behari, Srivastava, & Pandey, 2004; McKinley et al., 2009; Schrag, 2006; Slawek, Derejko, &
Lass, 2005). Additionally, the aforementioned cognitive and mood symptoms (e.g., depression)
frequently occur prior to the onset of motor symptoms (Tolosa, Compta, & Gaig, 2007); in fact,
early recognition may improve treatment options (e.g., Ravina et al., 2007). Since the focus of
this study will be on emotional expression, we will review these deficits in more detail.
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Vocal communication deficits. A deficit in vocal communication is another common PD
symptom that affects approximately 70 to 90% of individuals with PD (Hartelius & Svensson,
1994; Ramig et al., 2008). The collective term for the speech-related impairments in PD is
“hypokinetic dysarthria.” Symptoms of hypokinetic dysarthria include reduced vocal volume
(hypophonia), restricted vocal range, difficulty articulating consonants (hypokinetic articulation),
difficulty with the coordination involved with swallowing and speaking, a breathy or harsh vocal
tone, and dysregulated rate of speech (Schulz & Grant, 2000). The literature suggests that
individuals with hypophonia are frequently unaware of their low vocal volume and are likely to
overestimate the loudness of their speech during casual conversation, leading to the development
of this low vocal volume as their new baseline (Ho, Bradshaw, & Iansek, 2000; Liotti et al.,
2003). Additionally, many individuals with PD report difficulties initiating speech, which may
be related to akinesia, making it exceedingly difficult to maintain the typical back-and-forth
dialogue commonly seen in social interaction. Prosodic emotional expression deficits are also
documented in PD (Borod et al., 1990; McCabe et al., 2011; Zgaljardic et al., 2003), likely due to
the above symptoms. The aforementioned vocal impairments likely contribute to social
communication impairments in PD (Pell, Cheang & Leonard, 2006) and the resulting social
withdrawal and low self-esteem (Miller, Noble, Jones, & Burn, 2006).
Emotion processing deficits. There is a large body of literature documenting emotion
processing (i.e., expression and perception) impairments in PD. Deficits in emotional
expressivity are evident in both the facial (Borod et al., 1990; McCabe et al., 2016; Smith, Smith,
& Ellgring, 1996) and vocal channels (Borod et al., 1990; Zgaljardic et al., 2003) of individuals
with PD, although their subjective experience of emotion typically remains intact (for review,
see McCabe et al., 2010). Additionally, facial emotional perception deficits have been
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documented in the PD literature (Assogna, Pontieri, Caltagirone, & Spalletta, 2008; Borod et al.,
1990; Jacobs, Shuren, Bowers, & Heilman, 1995; Kan, Kawamura, Hasegawa, Mochizuki, &
Nakamura, 2002; Yip, Lee, Ho, Tsang, & Li, 2003).
Facial emotional expression. Impairment in facial emotional expression, termed
“masked facies” (Borod et al., 1990; Smith et al., 1996), is a common motor symptom of PD,
characterized by a reduction in speed, elasticity, and coordinated muscle movement involving the
brow, eyes, cheeks, and lips (Tickle-Degnen, Zebrowitz, & Ma, 2011). PD patients display
greater facial expressivity deficits when producing spontaneous facial expressions (involuntary)
versus posed expressions (volitional) of emotion (for review, see Borod & Koff, 1984). Of note,
a large body of research (over 70 years) suggests that posed and spontaneous facial expressions
are mediated by distinct neural mechanisms (Borod & Koff, 1984). Posed facial expressivity
impairments are commonly due to cortical lesions in the motor strip or in the corticobulbar
projections from the motor strip to the brainstem (Rinn, 1984, 2007). Deficits in spontaneous
expression are usually caused by subcortical (usually basal ganglia-related) dysfunction (Borod,
Haywood, & Koff, 1997; Borod & Koff, 1984; Dumer et al., 2014; Rinn, 1984). The basal
ganglia are the primary brain area impacted by PD. A large body of research has documented
posed and spontaneous facial emotional expressivity impairments in PD and addresses how these
deficits differ from the participants’ subjective experience of emotion, which usually remains
intact (for review, see McCabe et al., 2010).
Posed versus spontaneous facial expression of emotion. Individuals with PD typically
present with significant deficits in spontaneous facial emotional expression while displaying less
impairment in posed facial expression, although generally not as intact as healthy individuals
(e.g., McCabe et al., 2010; Simons, Pasqualini, Reddy, & Wood, 2004). Smith and colleagues
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(1996) used the Facial Action Coding System (FACS; Ekman & Friesen, 1978) to examine the
difference between posed and spontaneous facial emotional expression in individuals with PD
for 5 discrete emotions (happiness, sadness, fear disgust, and anger). They found that the
individuals with PD displayed less facial mobility and expressed facial emotions with less
intensity than healthy controls when producing spontaneous facial expressions elicited by
emotionally salient popular film segments. Posed emotional expressions were elicited by
instructing participants to display how their face would look while experiencing each of the five
discrete emotions. The authors found that although the posed expressions of happiness produced
by the PD participants were lower in intensity than those produced by the healthy controls, this
difference was not significant, and, overall, there were no significant differences among healthy
controls, mild PD participants, and moderate PD participants for posed facial emotional
expressions (Smith et al., 1996). Additionally, the PD participants’ ratings of subjective
emotional experience were similar to ratings made by the healthy controls, consistent with Borod
et al. (2008). Katsikitis and Pilowsky (1988) examined spontaneous facial emotional expression
elicited by viewing cartoons. They found that participants with PD smiled less frequently and
displayed a reduced range of movement (i.e., opened their mouths less) than did healthy controls.
Overall, the literature suggests that individuals with PD display more deficits in spontaneous
than posed facial expression, which may contribute to negative social consequences.
Facial mimicry. Facial mimicry is defined as the spontaneous echoing of the distinct
facial muscle movements and expressions of others (Hess & Fischer, 2013; Hietanen, Surakka, &
Linnankoski, 1998; Lang, Greenwald, Bradley, & Hamm, 1993). Healthy individuals are able to
quickly and, often, unconsciously react to the facial expression of their conversation partner by
mimicking their facial muscle movements (Dimberg, Thunberg, & Elmehed, 2000), which
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promotes effective social interaction and increases the accuracy and speed of emotional
perception (e.g., Chartrand & Barch, 1999; Niedenthal, 2007; Niedenthal, Brauer, Halberstadt, &
Innes-Ker, 2001; Oberman, Winkielman, & Ramachandran, 2007; Sonnby-Borgström,Jönsson,
& Svensson, 2003; Stel & van Knippenberg, 2008; Wood, Rychlowska, Korb, & Niedenthal,
2016). According to prior studies, individuals who display slower and restricted facial movement
are judged as being insincere (Pentland, Gray, Riddle, & Pitcairn, 1988; Pitcairn, Clemie, Gray,
& Pentland, 1990), as it may appear to the conversation partner that the person with facial
mimicry impairment is either not paying attention or empathizing (when appropriate) with their
narrative. Multiple PD motor symptoms, namely, akinesia, bradykinesia, and hypokinesia, are
likely to negatively impact one’s ability to mimic the facial movements of others. Akinesia
(slowed movement initiation) and bradykinesia (reduced speed of movement) could delay or
eliminate the facial mimicry response, whereas hypokinesia (restricted amplitude of movement)
could reduce the intensity of facial mimicry (Berardelli, Rothwell, Thompson, & Hallett, 2001;
Jankovic, 2008; Ling, Massey, Lees, Brown, & Day, 2012; Livingstone, Vezer, McGarry, Lang,
& Russo, 2016; Péron, Dondaine, Le Jeune, Grandjean, & Vérin, 2012). Studies suggest that
there is a link between facial mimicry and the perception of emotion, such that eliminating facial
mimicry responses in healthy individuals through experimental manipulation reduces the speed
of emotion perception (Niedenthal et al., 2001; Oberman et al., 2007). A recent study evaluating
the presence and extent of facial mimicry deficits in PD evaluated the facial mimicry response of
27 non-depressed PD patients and 28 age-matched controls through facial muscle
electromyography (EMG) recordings while they watched videos and listened to audio-recordings
involving calm, happy, sad, angry, and fearful emotions. The recordings consisted of neutral
statements (e.g., “Dogs are sitting by the door.”) produced in a calm, happy, sad, angry, or
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fearful tone of voice by experienced professional actors (2 male and 2 female). As the
participants were watching the video stimuli, their facial mimicry responses were recorded via
EMG. The researchers found that PD participants displayed significantly lower amplitude (little
to no movement) and delayed onset (beginning approximately 350 milliseconds later) of the
zygomaticus muscle region following happy stimuli relative to healthy controls. Similarly,
individuals with PD evidenced weaker activity in the medial frontalis region following the
presentation of sad stimuli as compared to healthy controls. In contrast, PD patients and healthy
controls showed similar activation of the corrugator supercilii muscle area in response to sad and
fearful presentations. In sum, PD patients displayed profound deficits in the facial mimicry of
positive emotions, with relatively intact mimicry for negative emotions (Livingstone et al.,
2016). The ventral striatal region of the basal ganglia, a region typically impacted by PD
pathology, is associated with the processing and regulation of positive emotions, such as
happiness (Hamann & Mao, 2002; Kim & Hamann, 2007), whereas the medial prefrontal and
anterior cingulate cortex (a brain region that is less impacted by PD) is involved with the
processing of negative emotions. The above findings are consistent with previous literature
showing that individuals with PD are perceived as looking more negative and withdrawn since
they produce smiles with less frequency and intensity (Pentland, Pitcairn, Gray, & Riddle, 1987;
Pitcairn et al., 1990). Additionally, previous studies have reported positive relationships among
the intensity, frequency, and duration of zygomaticus muscle activation and self-reported
happiness (Cacioppo, Petty, Losch, & Kim, 1986), suggesting that reduced smiling mimicry may
negatively impact subjective positive affect.
Emotional experience. Emotional experience has been defined as the subjective
experience of emotion based on the evaluation of physiological arousal patterns in response to
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stimuli (Barrett, 2006; Dalgleish, 2004). The facial feedback hypothesis (FFH) supports the
theory that facial expression may influence emotional experience (e.g., Buck, 1980; Davis,
Senghas, & Ochsner, 2009; Izard, 1971) through feedback from facial muscles. More
specifically, the FFH proposes that facially expressive movements (e.g., smiling by pulling back
the corners of one’s mouth and showing the teeth) may use a bottom-up neural mechanism to
enhance the corresponding emotional experience (Buck, 1980). Of note, multiple studies have
found a relationship between facial expressivity and emotional experience, such that reduced
facial expressivity is correlated with reduced intensity of emotional experience (Borod et al.,
2008; Davis et al., 2009; McIntosh, 1996; Montreys & Borod, 1998; Niedenthal, 2007; Strack,
Martin, & Stepper, 1988). Additionally, multiple behavioral (Adelmann & Zajonc, 1989; Davis,
Senghas, Brandt, & Ochsner, 2010; Mori & Mori, 2009, 2010; Niedenthal, 2007; Soussignan,
2002; Strack et al., 1988) and neuroimaging studies (Hennenlotter et al., 2009; Wiens, 2005) also
support the FFH. To illustrate, a classic study supporting FFH examined the emotional
experiences of individuals who were required to read comedic cartoons while holding pens in
their mouths in ways that inhibited or facilitated smiling. The participants with facilitated smiles
reported finding that they rated the cartoons as funnier than the participants in the inhibited
smiling condition (Strack et al., 1988). More recently, Davis et al. (2010) evaluated the selfreported emotional reaction of individuals who had received facial Botox injections (which
resulted in temporary partial facial paralysis) while watching emotionally arousing video clips.
They found that the participants in the Botox condition did not differ from controls in their
reactions to strong negative or strong positive video stimuli, however, they showed lower
emotional reactions than did healthy controls to mildly positive stimuli (Davis et al., 2010).
Based on these findings, one may logically believe that individuals with PD would report
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decreases in subjective emotional experience as they typically have severe facial expressivity
deficits (e.g., Borod et al., 1990; McCabe et al., 2010; Smith et al., 1996). However, the literature
suggests that individuals with PD experience emotion similarly to healthy individuals (e.g.,
Borod et al., 2008; Mikos et al., 2009; Smith et al., 1996; Vicente et al., 2011), despite the welldocumented profound facial expressivity deficits (Borod et al., 1990; Smith et al., 1996).
Evidence from the PD literature, in conjunction with the Davis et al. (2010) study, suggests that
facial emotional expression may have a subtle impact on subjective emotional experience, but
not enough to be impairing to individuals with PD.
Emotional perception. Many studies have documented impairments among individuals
with PD in the perception of negative discrete emotions, including fear, disgust (Kan et al., 2002;
Sprengelmeyer et al., 2003; Yip et al., 2003), anger (Sprengelmeyer et al., 2003), and sadness
(Sprengelmeyer et al., 2003; Yip et al., 2003). In addition, higher intensity of facial emotional
expression does not improve perception accuracy in individuals with PD (Dujardin et al., 2004).
Interestingly, there is a body of literature suggesting that the side of initial motor symptoms in
PD may play a role in emotion perception deficits. Individuals with left-sided onset of motor
symptoms display deficits in the perception of sad (Ariatti, Benuzzi, & Nichelli, 2008) and angry
faces (Clark, Neargarder, & Cronin-Golomb, 2008; 2010), whereas individuals with right-sided
motor symptom onset show impaired perception of fear (Ariatti et al., 2008) and surprise (Clark
et al., 2008, 2010). A recent study investigating the contribution of motor symptom onset (left
versus right) to the neural processing of dynamic face stimuli found that PD participants with
left-sided motor symptom onset showed significant dynamic face processing deficits compared
to healthy controls (Garrido-Vásquez, Pell, Paulmann, Sehm, & Kotz, 2016), consistent with the
right-hemisphere hypothesis (e.g., Borod, 1996; Cattaneo et al., 2014; Kanwisher & Yovel,
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2006). However, they found no significant differences among left-sided onset PD, right-sided
onset PD, and controls on static facial recognition via the Benton Facial Recognition Test
(Garrido-Vásquez et al., 2016), consistent with previous research showing no asymmetry effects
or significant differences between PDs and controls in the processing of facial emotion (Blonder,
Gur, & Gur, 1989; St. Clair, Borod, Sliwinski, Cote, & Stern, 1998; Ventura et al., 2012).
Despite the disparate findings, there are studies pointing to pronounced deficits in the recognition
and processing of facial emotion, which can lead to the misreading of nonverbal social cues and
subsequent inappropriate responding to emotionally sensitive situations, thus, impairing social
communication. Of note, this deficit is only seen in the perception of negative emotions (e.g.,
Ariatti et al., 2008; Clark et al., 2008, 2010).
Gender differences in emotion processing. Gender differences in the processing of
emotion have been well documented in the literature (e.g., for reviews, see Borod et al., 2004;
Borod & Madigan, 2000). Women experience emotions with higher intensity (Birditt &
Fingerman, 2003; Fujita, Diener, & Sandvik, 1991; Grunwald et al., 1999) and produce more
pronounced facial emotional expressions (Hall & Matsumoto, 2004; Scholten, Aleman,
Montagne, & Khan, 2005; Thayer & Johnsen, 2000) than do men. There is also evidence
documenting that women use more facial muscle movements when expressing negative emotions
(e.g., sadness, anger, and fear; Schwartz, Brown, & Ahern, 1980) and smile more frequently than
men (LaFrance, Hecht, & Paluck, 2003).
To our knowledge, there are no studies specifically documenting gender differences in
facial emotional expressivity in PD. However, there is some evidence of gender differences in
the clinical presentation of PD, such that more women initially present with tremor, whereas men
present with bradykinesia or rigidity (Haaxma et al., 2007). Tremor is usually present in the
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extremities, whereas bradykinesia and rigidity are likely to affect the face. Coupled with the
evidence suggesting that men are already less expressive than women, it is likely that men will
present with more facial expressivity deficits than will women.
Impression Formation Regarding PD: Social Consequences
Impression formation is a form of perception that involves many aspects of a person (e.g.,
physical appearance, facial expression, and speech) in order to form a judgment about that
person (e.g., Schneider, Hastorf, & Ellsworth, 1979). Research on impression formation shows
that individuals frequently make long-lasting inferences and judgments about others based on
very limited information (Epley & Gilovich, 2006; Schneider et al., 1979). Our ability and
natural tendency to form impressions and judgments of others during social interactions may be
mediated by facial expressivity. For instance, a study investigating the role of facial expressivity
in impression formation in healthy participants (Riggio & Friedman, 1986) found that increased
levels of facial emotional variability (i.e., the number of noticeable changes from the poser
participants’ typical neutral expression) were consistently related to more favorable first
impression ratings.
Findings from other studies have investigated the social consequences of reduced facial
expressivity in PD patients. Impairments in facial expressivity frequently interfere with social
communication in PD, potentially due to inaccurate impressions formed by lay people regarding
their facial expressions (Brozgold et al., 1998; Hemmesch, Tickle-Degnen, & Zebrowitz, 2009),
as well as by healthcare professionals (Lyons, Tickle-Degnen, Henry, & Cohn, 2004; TickleDegnen et al., 2011; Tickle-Degnen & Lyons, 2004). A study by Brozgold et al. (1998),
examining the relationship between facial emotional intensity and social functioning in patients
with PD, right-hemisphere brain damage, unipolar depression, and schizophrenia and in
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demographically-matched healthy control participants, found a positive relationship between the
intensity of facial expressivity and social functioning (i.e., the more expressive a person’s facial
emotional expressions, the higher their ratings of social functioning). The results of this study
revealed that individuals with PD displayed reduced facial expression intensity and, more
specifically, greater negative and reduced positive facial emotional expressions, which could
account for their difficulty with social functioning (Brozgold et al., 1998). A study examining
emotional frequency in patients with PD (Pitcairn et al., 1990) found that their facial expressions
were rated as less frequent than those of healthy controls and that their positive facial
expressions of happiness (e.g., smiling) were rated as “phony,” likely due to delayed (slowed
initiation) facial response as well as less facial muscle involvement.
Tickle-Degnen et al. (2011) examined the effect that facial masking in PD has on the
impressions formed by American and Taiwanese health-care practitioners. The health
practitioners, who were well informed about facial masking, included 159 professional clinicians
and 125 students in training. The researchers found that clinicians from both cultures judged PD
patients with more facial masking as more depressed, less sociable, less socially supportive, and
less cognitively competent than patients with less facial masking. Additionally, according to
Hemmesch et al. (2009), older healthy adults reported less interest in starting relationships with
women diagnosed with PD and presenting with facial masking than men with PD who had
similar facial symptoms. These findings support the notion that these social consequences are
likely more severe for women due to the different role that socialization plays in the lives of
women versus men (Solimeo, 2008). Results from our laboratory supplement and support these
findings, showing that the personality characteristics of PD patients (i.e., extraversion,
dependence, anxiety, and likability) were perceived more negatively by naïve raters when
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compared to those of age- and gender-matched healthy controls (Dumer et al., 2013). The results
from these studies suggest that casual social partners, as well as experienced clinicians, are likely
to use facial expressivity to form impressions about patients’ personality traits. Since personality
traits are conceptualized by most lay people as well as researchers to be stable over time and
across different situations (McCrae & Costa, 2003), inaccurate judgments of the personality of
individuals with PD may affect future social interactions with the same people over time, leading
to more problematic relationships with family members and healthcare providers. This is of
particular concern for individuals with PD since their facial expressivity will likely become a less
and less reliable reflection of their internal emotional states as the disease progresses, potentially
worsening social communication and contributing to biased impressions.
The biased impressions that can result from impaired facial expressivity can support
interpersonal self-fulfilling prophecies, such that the individual may act in a way that will
confirm the biased impression experienced by their conversation partner (e.g., Snyder, Tanke, &
Berscheid, 1977). For instance, as indicated above, recent studies (Tickle-Degnen et al., 2011)
have suggested that clinicians form the impression that patients with higher levels of facial
masking are less psychologically, cognitively, and socially capable, as well as more negative and
less engaged, than those with lower levels of masking. Such impressions may, in turn, lead to
interviewing or interacting differently with patients with higher facial masking levels, which
could lead to the elicitation of different behaviors. A study (Takahashi, Tickle-Degnen, Coster,
& Latham, 2010) evaluating the difference in facial expressivity response between PD patients
asked adaptive coping questions (e.g., “What did you find satisfying last week?”) versus
problem-oriented questions (e.g., “What did you find difficult last week?”) found that
interviewers asking positive adaptive coping questions elicited more positive facial expressivity

15

and less facial masking than those that asked problem-oriented questions. In addition, the
patients who were asked more problem-oriented questions were judged as being more hopeless
and apathetic during their interview relative to patients with lower levels of facial masking
(Takahashi et al., 2010). These biased observations and interviewing styles may result in
negative medical consequences, such as ill-suited treatment plans or misdiagnoses.
Evidence from longitudinal studies of PD show that individuals with PD report feeling
more emotionally vulnerable and socially isolated as the disease progresses (Alves, WeentzelLarsen, Aarsland, & Larsen, 2005; Forsaa, Larsen, Wentzel-Larsen, Herlofson, & Alves, 2008;
Karlsen, Tandberg, Årsland, & Larsen, 2000; Post et al., 2011), possibly due to communication
difficulties related to the progression of motor and facial expressivity deficits. This is
problematic as social support and engagement are important for the physical and mental health,
as well as the quality of life of older adults (Buchman et al., 2009; Holt-Lunstad, Smith, &
Layton, 2010; Pinquart & Sörensen, 2000).
Channel Compensation
There is evidence from the Facial Palsy (FP) literature that individuals may compensate
for facial expressivity deficits through other channels of communication (e.g., Bogart, TickleDegnen, & Ambady, 2014). Individuals with FP experience similar social consequences (e.g.,
misinterpreted as unfriendliness and disengagement) as individuals with PD due to reduced or
asymmetrical facial expressivity (Bogart et al., 2014; Hemmesch et al., 2009; Tickle-Degnen &
Lyons, 2004). The study by Bogart and colleagues (2014) investigated impressions of 27
individuals with FP using a thin-slice design, meaning that rater participants (termed
“perceivers;” 121 university students who were blind to the FP severity and to the study
hypotheses) viewed and rated short (20-second) video clips of individuals with severe and mild
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unilateral and bilateral FP. The perceivers were randomly assigned to one of the following
channel conditions: 1) face, voice, voice + speech, 2) body, voice + speech + body, or 3) all four
channels. Next, the perceiver participants rated the facial expressivity, as well as compensatory
expressivity (i.e., use of vocal and bodily expression), from “1” (low expressivity) to “5” (high
expressivity). They found that the perceivers rated severe FP individuals as displaying
significantly less happiness than those with mild FP but rated them as equally sad, congruent
with the PD literature showing that higher levels of facial masking lead to less positive
evaluations from peers, family members, and professionals (Hemmesch et al., 2009; TickleDegnen et al., 2011; Tickle-Degnen & Lyons, 2004). However, the more communication
channels that the raters observed, the higher they rated the emotional expression intensity (for
both happiness and sadness) of the perceived FP participant, suggesting that individuals with
facial palsy may be able to compensate for reduced facial expressivity through other
communication channels (Bogart et al., 2014). However, unfortunately, individuals with PD
frequently display deficits in multiple channels of emotional expression (i.e., face, voice, and
body; for reviews, see Borod et al., 1990; Jankovic, 2008; McCabe et al., 2010; Ramig et al.,
2008), emphasizing the need for treatments that target multiple aspects of motor impairment.
Rehabilitation Treatments
Lee Silverman Voice Treatment. The clinical rehabilitation literature has documented
multiple types of voice and speech therapies that are aimed at the rehabilitation of speech and
vocal symptoms. The only voice treatment demonstrating long-term effectiveness is the Lee
Silverman Voice Treatment (LSVT; Ramig et al., 1995; Ramig, Fox, & Sapir, 2011; Ramig,
Sapir, Fox, & Countryman, 2001; Sapir, Ramig, & Fox, 2011). LSVT is a voice therapy that
targets common speech and motor symptoms of PD, including vocal loudness, swallowing, limb
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gesture, and limb function. The focus of LSVT is to maximize vocal loudness, optimize
phonatory effort, and increase accurate perception of loudness during speech. In addition to
targeting vocal and speech deficits, there is anecdotal evidence from the patients themselves and
their spouses (Speilman, Borod, & Ramig, 2003) and quantitative evidence from preliminary
studies suggesting that LSVT indirectly improves facial expressivity (Alterescu, 2012; Alterescu
et al., 2013; Spielman et al., 2003).
LSVT is thought to improve facial expressivity due to the theory of an integrated system
of emotion suggesting that facial and prosodic communication channels work together when
producing an emotional response (Borod, 1993b; Kaiser & Scherer, 1998; Porges, 2001). Strong
empirical evidence supporting these theories includes positive relationships between facial and
prosodic expression in healthy adults (Borod et al., 1985; Malatesta, Davis, & Culver, 1984) and
in neuropsychiatric populations (Borod et al., 1985, 1990). Due to this relationship, improvement
in one component of emotional expressivity through LSVT (i.e., intonational and prosodic
expression) may exert influence on another component (e.g., facial expressivity). There is also
neurological evidence supporting this theory: facial and vocal systems display similar neural
pathways for posed and spontaneous emotional expression. Posed expression is mediated via
neocortical pathways whereas spontaneous expressions are mediated by subcortical and limbic
pathways (for reviews, see Borod, 1993a; Borod & Koff, 1984). In addition, there is considerable
overlap between the neural structures regulating facial and vocal expression, including the
anterior cingulate cortex, peraqueductal grey, thalamus, and basal ganglia (Devinsky, Morrell, &
Vogt, 1995; Jurgent & Zwirner, 1996). Neural evidence of vocal and facial systems working
together to produce speech sounds is demonstrated through neural coupling between orofacial
muscle systems and laryngeal and respiratory structures (McClean & Tasko, 2002).
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Articulation Treatment. Articulation Treatment (ARTIC), also developed by Ramig and
colleagues (Ramig et al., 1995; Spielman et al., 2012) is a control treatment for LSVT to be used
in PD populations. ARTIC, therefore, is structured to be as similar to LSVT as possible with
respect to the number of sessions, treatment length, clinician contact, and amount of feedback.
The main focus of ARTIC is articulatory effort, and participants are asked to repeat overarticulated vowel-vowel, consonant-consonant, and vowel-consonant sounds. Evidence from a
subset of this dataset found that ARTIC does not significantly improve facial expressivity
(Alterescu, 2012). The theoretical basis for the differential findings between LSVT and ARTIC
is that ARTIC targets higher level components of speech production (i.e., articulation),
controlled by the neocortex, whereas LSVT targets more primitive aspects of vocal production
(e.g., respiration and phonation), exerting its influence on older phylogenetic brain regions (e.g.,
subcortical areas), which are more involved in emotional processing and are more affected in
PD.
Predictors of outcome in rehabilitation treatments. A significant amount of effort is
contributed by patients, their families, and medical professionals in determining the most
efficacious treatment for a particular patient. It is, therefore, important to investigate variables
(e.g., demographic, cognitive, and mood) that may impact treatment outcome to increase
confidence that patients are engaging in the proper treatment. Prior research examining factors
influencing rehabilitation treatment outcome has yielded variable results, with some reports that
cognitive status (Fusco et al., 2009; Hershkovitz, Gottlieb, Beloosesky, & Brill, 2006; Landi et
al., 2002), age (Nieuwboer, De Weerdt, Dom, & Bogaerts, 2002), disease severity (Nieuwboer et
al., 2002), depression (Fusco et al., 2009), and level of motoric function (Ellis et al., 2008) play a
role in predicting successful outcome. Most of these studies consisted of stroke or mixed
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geriatric populations (including individuals with PD) and studied improvement in physical
therapy or activities of daily living.
To our knowledge, only one study investigated rehabilitation outcome based on clinical
characteristics of individuals with Parkinson’s disease. Nieuwboer and colleagues (2002)
evaluated whether clinical factors, including disease severity (measured by the Unified
Parkinson’s Disease Rating scale, UPDRS; Fahn & Elton, 1987), cognitive ability (measured by
the Mini-Mental Status Exam [MMSE]; Folstein, Folstein, & McHugh, 1975), age, and mood
(measured by the Geriatric Depression Scale; Montorio & Izal, 1996) can predict functional
outcome following physiotherapy in home- and hospital-based settings. They found that disease
severity was the only predictor of short-term physiotherapy treatment benefit in the home setting
and that none of the factors predicted functional outcome in hospital settings. Cognitive status
and age predicted maintenance of gains at follow-up. Prediction studies of this nature can help to
improve appropriate treatment selection for patients with PD.
Aims and Hypotheses
Aim 1. We examined differences in facial emotional expressivity (i.e., emotional
frequency [EF], emotional variability [EV], emotional intensity [EI], &social engagement [SE])
and facial mobility (FM) between PD participants and demographically-matched healthy adult
control participants (HCs), as well as between men and women, using the pretreatment baseline
data.
Hypothesis 1. We hypothesized that PD patients would display significantly reduced
facial expression (i.e., EF, EV, EI, and SE) and facial mobility (FM) compared to HCs due to
substantial evidence showing facial expression impairments in PD (e.g., Borod et al., 1990;
Brozgold et al., 1998; Katisikitis & Pilowsky, 1988; Smith et al., 1996).
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Hypothesis 2. We predicted that PD patients would display reduced facial emotional
expressivity in positive versus negative monologues based on literature showing that PD patients
are better at expressing negative than positive emotion (e.g., Brozgold et al., 1998; McCabe,
2013; Pitcairn et al., 1990).
Hypothesis 3. We predicted that women would be significantly more facially expressive
than men in both PD and HC groups due to evidence showing that women are perceived as more
emotionally expressive than men (Borod & Madigan, 2000; Hall & Matsumoto, 2004; Huang &
Hu, 2009; Scholten, Aleman, Montagne, & Kahan, 2005; Thayer & Johnson, 2000).
Aim 2. We examined changes in facial emotional expression (EF, EV, EI, and SE) and
mobility (FM) over time from baseline to post-treatment for the Lee Silverman Voice Treatment
(LSVT) and Articulation Treatment (ARTIC) PD groups and from baseline to 4-5 weeks later for
untreated groups (i.e., UPDs and HCs).
Hypothesis 4. We predicted that PD patients in the LSVT group would display
significantly more change over time in facial emotional expressivity (EF, EV, EI, and SE) than
will PD participants treated with ARTIC, Untreated PDs, and HCs. An empirical rationale for
this hypothesis is based on earlier findings with LSVT in PD showing significant improvements
in facial expression (Alterescu et al., 2013; Spielman et al., 2003). A theoretical rationale for PD
patients’ improvement in LSVT (e.g., Bono & Borod, 2016) is that the treatment focus is on
respiration and vocal loudness, which has been found to engage subcortical structures within the
basal ganglia, which are involved in voice production as well as facial emotional processing.
Hypothesis 5. We hypothesized that ARTIC would improve EF, EV, EI, SE, and FM
over time significantly more than PD participants receiving no treatment and healthy control
participants, but to a lesser extent than LSVT. We are making this prediction since ARTIC
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focuses on articulation, which engages more frontal cortical structures, which do not affect
emotional expression as much as subcortical structures (Alterescu, 2012; Liotti et al., 2003;
McClean & Tasko, 2002).
Hypothesis 6. We predicted that PD patients in the LSVT and ARTIC groups would
show more improvement over time for negative versus positive monologues based on literature
showing that PD patients are better at expressing negative than positive emotion (e.g., Brozgold
et al., 1998; McCabe, 2013; Pitcairn et al., 1990).
Aim 3. We proposed to extend the rehabilitation literature through examining whether
demographic (age, gender, & years of education), cognitive (Mini Mental Status Exam [MMSE];
Folstein, Folstein, & McHugh, 1975), clinical (Hoehn & Yahr Stage, illness duration, & side of
initial motor symptom), and affective (Beck Depression Inventory, Second Edition [BDI-II];
Beck, Steer, & Brown, 1996) status can predict changes in facial expressivity following LSVT.
Hypothesis 7. Based on previous literature (e.g., Ellis et al., 2008; Fusco et al., 2004;
Hershkovitz & Brill, 2007; Landi et al., 2002; Nieuwboer & Weerdt, 2002), we predicted that
lower age, Hoehn and Yahr Stage, PD duration, and BDI-II scores and higher years of education
and MMSE scores would predict more change for the LSVT group. We also predicted that PD
individuals with right-onset motor symptoms (RPDs) would display more change in facial
expression following LSVT than PDs with left-onset motor symptoms (LPDs), based on findings
from a subset of these data suggesting that individuals with RPD show higher levels of facial
expressivity than those with LPD (e.g., Bono et al., 2017), in addition to neuropsychological
studies regarding right-hemisphere specialization for facial emotional expression (e.g., Borod,
2000).
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Methods
Participants
There are two sets of participants involved in this study: “posers” and “raters.”
Posers. The “posers” are the participants involved in the treatment portion of the study
and were recruited as part of a larger study conducted through the laboratory of Lorraine O.
Ramig, Ph.D. from the University of Colorado at Boulder. Participants were recruited from the
Denver and Boulder regions through physician referrals, PD support groups, senior citizen
centers, and IRB-approved advertisements. All participants were recruited and treated in
accordance with the guidelines and standards set forth by both the Colorado Multiple
Institutional Review Board (COMIRB) at the University of Colorado at Boulder and the
Institutional Review Board (IRB) at Queens College of the City University of New York.
Written informed consent was obtained from each participant, and participants were notified that
they could discontinue at any time. All poser participants were financially compensated $10 for
the screening process and $30 for their participation in the experimental treatment phase.
All PD participants were screened to determine eligibility for inclusion into the treatment
phase of the study. Exclusion criteria included presence of moderate to severe cognitive
impairment (assessed by a Mini-Mental Status Examination [MMSE] score of 26 or below;
Folstein, Folstein, & McHugh, 1975); severe depression (as measured by a Beck Depression
Inventory-II [BDI-II] score of 28 and above; Beck et. al., 1996); substance use disorders
(including tobacco smoking); symptoms of a neurological condition other than PD (as diagnosed
by a neurologist); history of cancer, gastrointestinal pathology, and/or laryngeal pathology;
presence of any other disorder (other than PD) that could impair speech and language; severe
temporomandibular joint (TMJ) disorder; pregnancy; and participation in any other intensive
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speech treatment within the last two years. All participant history was evaluated by specialists,
including otolaryngologists, neurologists, and speech-language pathologists.
The posers consisted of 40 individuals with idiopathic PD (PD; 67.5% male; M age=66.8,
SD=8.6) and 14 demographically-matched healthy control participants (HCs; 60% male; M age=
65.5, SD=8.3). There were three groups of PD posers, including 13 PD patients receiving LSVT
(69.2% male; M age=66.7, SD=6.6), 14 PD patients receiving an articulation control treatment
(ARTIC; 64.2% male; M age=68.4, SD=10.2), and 13 PD patients receiving no treatment (UPD;
69.2% male; M age=65.3, SD=8.8). Demographic and clinical data were collected at baseline for
all participants for screening purposes, including age, gender, years of education, BDI-II score,
and MMSE score. For PD participants, Hoehn & Yahr Stage (Hoehn & Yahr, 1967), years since
PD diagnosis, and side of initial motor symptoms were collected as well. Side of motor-symptom
onset was based on self-report and information obtained from medical records.
Treatments. The Lee Silverman Voice Treatment (LSVT LOUD ©; Ramig et al., 1995;
Ramig, Fox, & Sapir, 2011; Ramig, Sapir, Fox, & Countryman, 2001; Sapir, Ramig, & Fox,
2011) is a voice treatment that has been established in the treatment of Parkinson’s disease.
LSVT stimulates the respiratory/phonatory system to improve healthy vocal loudness in speech
production. Exercises include sustained vowels (“ah”), pitch exercises, and generalization of
improved loudness to speech production. Patients are encouraged to sustain vowels as loudly and
for as long as they can at high and low pitches. This is done to increase their vocal range in
addition to vocal loudness for the purposes of more expressive and audible speech. Therapists
will also record the patient so that they can have audible feedback throughout the process, since
many PD patients are not reliable judges of their own vocal volume (Ho, Bradshaw, & Iansek,
2000). This helps to retrain sensory perception and internal cueing. During week one of LSVT,
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the patients are encouraged to use their loud vowel voice to produce words and short phrases at
the same volume; this is increased to sentences in week 2, to paragraphs in week 3, and to
engaging in fluid dialogue with the therapist during week 4. This standardized treatment includes
16 individual 60-minute sessions 4 times per week for 4 weeks and includes daily homework to
emphasize the generalizability of skills learned in therapy to daily life.
Articulation Treatment (ARTIC) is a speech treatment (Spielman et al., 2012) that was
designed to be as similar to LSVT as possible, except that it focuses on the articulatory system.
Tasks include many repetitions of over-articulated consonant combinations (e.g., /t-k/),
consonant vowels (e.g., “pa”), consonant vowel consonants (e.g., “tat”), vowel-vowel
combinations (e.g., “oo-ee-oo-ee;” Dumer et al., 2012), and generalization of improved
articulation to speech production. Similar to LSVT, patients are encouraged to use their skills to
produce words, phrases, full sentences, paragraphs, and fluid conversations while focusing on the
articulation of their words (as opposed to the vocal loudness in LSVT). ARTIC also consists of
16 individual 60-minute sessions, 4 times per week for 4 weeks; includes daily homework and
carryover; and focuses on retraining sensory perception and internal cueing. Treatment outcomes
for both speech therapies were measured by several voice criteria, including vocal loudness and a
sound pressure measure.
Raters. Raters included 18 undergraduate students from Queens College, CUNY who
were recruited to be trained to rate videos of facial expressions that were obtained from the
posers at baseline and post-treatment. Raters were recruited in three cohorts (50% male) through
the use of IRB-approved flyers posted throughout the Queens College campus. All raters were
given IRB-approved consent forms before starting the training and rating sessions. Raters were
trained and paid $9 per hour for their time spent during training and rating sessions. Inclusion
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criteria for raters consisted of the following: Caucasian, between the ages of 20 and 35, righthanded, and a native English-speaker (i.e., individuals who learned to speak English by age 7).
Only Caucasian raters were recruited for this study, because the posers were almost exclusively
Caucasian due to the minimal diversity of the geographical area (i.e., Boulder, CO) from which
the poser participants were recruited. This decision was made due to the “in-group advantage”
(Elfenbein, Beaupre, Levesque, & Hess, 2007), which supports the theory that individuals are
more accurately able to perceive the emotional expressions of members of their own cultural
group rather than those from other groups (Elfenbein et al., 2007). Exclusion criteria included
history of neurological or psychiatric disorders, head trauma, learning disabilities, and/or
substance abuse. Handedness and medical history were assessed through the verbal self-report of
the potential raters.
Procedures
Poser monologue procedures. For the emotion assessment, posers were seated in a
sound-resistant booth in a dental exam chair with a headrest. Posers in all four groups were
videotaped while prompted to recall and speak about a happy, sad, and angry emotional event,
using monologue elicitation procedures from the New York Emotion Battery (NYEB; Borod et
al., 1992; Montreys & Borod, 1998) at two time points (baseline and about one-month postbaseline). For the two treatment groups (i.e., LSVT and ARTIC), NYEB evaluation took place
before and after treatment. For the two non-treatment groups (i.e., UPDs and HCs), the
procedure took place at the same time interval (approximately 4 to 5 weeks). The monologues
were elicited by an experimenter who was present for the duration of the procedure to give
instructions and guidance. The following paraphrased instructions from the NYEB were used
with the posers to elicit emotional monologues: “Please speak for approximately three 90-second
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intervals describing experiences when you felt intense sadness, happiness, or anger.” The video
data consisted of footage of the posers’ neck, face, and head and were recorded using a Canon
XL1S mini DV video-camera positioned approximately 9 feet away from the poser throughout
the monologues.
Poser voice treatment procedures. The clinicians facilitating the treatments (LSVT and
ARTIC) included three licensed and experienced speech-language pathologists. All clinicians
were female and treated PD patients in both treatment groups. The PD patients received all of
their treatment sessions from the same clinician. The treating clinician was not present during the
emotional monologues.
Monologue rating procedures. There were 3 cohorts of 6 raters, each evaluating about
1/3 of the data set. The posers chosen to be rated in each of the 3 cohorts were carefully selected,
with poser demographics, including age, gender, years of education, and illness severity for the
PD patients (Hoehn & Yahr stage; Hoehn & Yahr, 1967), matched as closely as possible across
the 3 cohorts. Each group of raters viewed randomized 15-second monologue segments for the 4
poser groups (LSVT, ARTIC, UPD, and HC) and rated each segment for each of the 5 variables
(emotional frequency [EF], emotional intensity [EI], emotional variability [EV], social
engagement [SE], and facial mobility [FM]). A 7-point Likert scale was used to make ratings
(“1” = no or minimal expression to “7” = maximal expression). Each rater rated the variables in
the same order, only one variable at a time, starting with FM, followed by EF, EV, EI, and SE.
FM had to be rated before the other variables because it represented facial muscle movements
without emotional content.
Facial expression was evaluated for 4 aspects of emotional expressivity (EF, EI, EV, and
SE) and for non-emotional facial mobility (FM). Frequency (EF) is defined as the number of
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facial emotional expressions observed by the rater during each video segment. Facial mobility
(FM) is a control (non-emotional) condition created to evaluate how much muscular movement
the face produces during each monologue segment. EF can refer to the total number of distinct
emotional expressions (e.g., a smile that indicates happiness following by trembling lips that
indicate sadness) or the number of the same repeated emotional expression (e.g., several smiles
separated by neutral facial expressions). Emotional Intensity (EI) is the intensity or amplitude
with which facial emotional expressions were produced only in the emotional portions of the
video segment (raters would not evaluate the intensity of a neutral face). Emotional variability
(EV) refers to the total number of different types of facial emotional expressions (e.g., anger
followed by sadness) or the total number of changes within the expression of a single emotion
(e.g., a smile followed by a laugh, followed by another smile). Social Engagement is a rating of
how engaged, attentive, connected, or involved the participant comes across facially to the rater.
Rater training procedures. All recruited raters were trained extensively by upper level
M.A. and Ph.D. students in Dr. Joan Borod’s Emotion Laboratory at Queens College to
experimentally rate facial expressivity using the rater training system developed by Canino,
Borod, Madigan, Tabert, and Schmidt (1999), including an exemplar, conferencing, and
interrater reliability training phases. Raters were trained with their respective cohort group (there
were 3 cohorts of raters, with 6 raters per cohort) to make the training sessions interactive and to
assess the reliability of the raters as a group once the training for each variable was complete.
The purpose of the training sessions was to train the raters to reliably rate each of the four facial
expression variables (EF, EI, EV, and SE) and the non-emotional control variable (FM) on a 7point Likert scale (“1” = no or minimal expression to “7” = maximal expression). For each rater
cohort, there was one training session held for each of the five face variables examined. Raters
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were taught to attend to many parts of the face and to notice the possible movements that may
occur (e.g., forehead can be wrinkled, vertical lines can be seen between the eyebrows, eyebrows
can be raised or lowered, eye gaze may shift, or corners of mouth may be drawn back and up).
Raters were also taught to disregard head movements, as well as movements that appeared to be
random and unrelated to facial emotional expression (e.g., body tremor, head shaking, and
excessive blinking), and to only attend to facial muscle movement. In addition, raters were
instructed to take note of and to disregard each poser’s unique facial features in the ratings (e.g.,
age wrinkles could be misinterpreted as movement). Raters were taught that emotional
expressions may occur in full form, that is, all parts of the face contributing to an expression of
happiness, or in partial form (e.g., only the eyes or eyebrows are expressing an emotion without
the accompanying expression in the mouth region) and to count both forms in their evaluation of
the five variables.
Exemplar training phase. This phase of training was primarily instructional. The raters
were introduced to the 7-point Likert scale, and the experimenter presented 14 15-second video
clips of the posers’ emotional and non-emotional monologues (two examples for each point on
the Likert scale presented in increasing order, from a rating of “1” to a rating of “7”).
Conferencing training phase. This phase of training was interactive, in that the goal was
for raters to reach a consensus. The experimenter presented the raters with 12 quasi-randomly
selected video segments and instructed each rater to independently rate the segment with the 7point Likert scale. After each rater independently made their ratings, they shared their ratings
with the group in order to determine if the raters achieved a sufficient level of consensus for each
segment. If this level of consensus was not reached, the experimenter again discussed the
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variable and tried to determine whether the low consensus was due to misunderstandings and/or
outlier ratings. After the discussion, raters viewed and independently rated that segment again.
Inter-rater reliability training phase. The purpose of this training phase was to assess the
inter-rater reliability of the raters as a cohort. Raters were instructed to rate 40 randomly selected
segments independently. After all ratings were made, the experimenters calculated the inter-rater
reliability for the rater cohort using average one-way random Intra-Class Correlations (ICC;
Shrout & Fleiss, 1979). Raters in each cohort were qualified to rate the facial data as long as
there was at least 75% agreement among raters’ responses (ICC ≥ .75).
Experimental rating phase. After completing the training sessions, raters were qualified
and performed ratings for each variable independently over 2 to 3 weeks in the same room on the
same Dell computer. All rating sessions were approximately 2 hours long and were supervised
by a lab member to ensure that the raters maintained adequate effort and attention throughout
their sessions and that distractions were eliminated. The raters were instructed to rate each
segment from 1 to 7 on the computer screen using the mouse after viewing the 15-second video
clip. Raters were able to view the same 15-second segment up to 3 times. When the ratings for a
specific variable (e.g., FM) were completed by all six raters, the training session for the next
emotional variable was scheduled.
Training materials. Each rater was provided with the following materials to rate the face
data.
Rating scale. Each rater received a training packet that included a copy of the 7-point
Likert scale they would use for rating, definitions of the variables, and specific guidelines for
recognizing facial muscle movements that are associated with discrete emotions at the beginning
of each training session.

30

Baseline faces. Raters were given a packet of baseline face photographs for each poser
for their reference during the rating of experimental data. The baseline face photographs were
color-printed pictures of emotionally neutral faces made by the posers, taken from the
experimental data. These baseline faces were created so that raters could effectively distinguish
true muscle movement or facial expressivity from facial age or Parkinsonian features that would
appear in the resting face.
Preparation of training segments. Video training segments were selected using quasirandom sampling, ensuring that these segments were balanced for emotion, gender, poser group,
and individual poser. The exemplar training segments were chosen by 3 to 5 lab members who
were blind to the poser information in each segment. After viewing each of the 14 segments for
each variable, each lab member independently made their own 7-point rating. The segments with
good interrater reliability (defined as all ratings within 1 point of each other) were selected for
the rater training sessions. When small discrepancies in ratings occurred, the final segment rating
would be based on a majority vote. This was the same procedure used to select the conferencing
training video segments.
Preparation of experimental video segments. Each 1.5 to 3 minute emotional and nonemotional poser monologue was divided into 15-second segments for rating purposes. This was
completed by using video editing software (i.e., Corel Video Studio ProX3) to eliminate any
irrelevant parts of the monologue (e.g., experimenter providing instructions to participant) from
the beginning and end of each monologue. The monologues were divided into 15-second
segments, starting from the end of the monologue and working backward. This procedure is
based on previous research (Kazandjian, Borod, & Brickman, 2007) suggesting that the most
emotionally intense sections within these types of monologues are at the middle and end of the
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monologue. As such, any discarded portions of the monologue that are too short to analyze (i.e.,
the very beginning of the monologue) are likely to be the least emotionally intense monologue
sections.
The clips were presented to raters on Dell computers with a video-stimulus presentation
software programmed into Microsoft Access version 2007. Presentation of video clips was
randomized, so that each rater rated the video segments in a different order than the other raters
in their cohort, preventing order effects with respect to individual rater, poser group, monologue
type, and gender. All video segments during training and experimental ratings were presented
without audio to prevent the influence of extraneous variables (i.e., intonational, prosodic, or
lexical/verbal expression) on the raters’ ratings.
Clinical and Demographic Variables for the Posers
Data for a number of demographic (i.e., age, gender, and years of education), clinical
(i.e., Hoehn & Yahr Stage, illness duration, and side of initial motor symptom), cognitive (i.e.,
MMSE), and affective (i.e., BDI-II) variables were collected at baseline and are described in
detail below.
Beck Depression Inventory-II (BDI-II). The BDI-II (Beck, Steer, & Brown, 1996) is a
21-item self-report inventory that assesses the intensity of depressed mood in clinical and healthy
populations. Each item addresses a symptom of depression according to the DSM IV-TR and
arranges multiple-choice responses in increasing severity order. Participants rate the severity of
each symptom (described in each item) on a four-point scale, ranging from “0” (lack of or
minimal symptom) to “3” (highest level of the symptom experienced). The total score for the
inventory ranges from “0” to “63,” with 0-13 indicating “minimal depression,” 14-19 “mild
depression,” 20-28 “moderate depression,” and 29-63 “severe depression” (Beck, Steer, &
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Brown, 1996). The BDI-II is a psychometrically sound instrument (Coefficient Alpha = .92,
based on a clinical sample; Coefficient Alpha = .93, based on a non-clinical sample; Beck, Steer,
& Brown, 1996). For our sample, we screened for severe depression and excluded participants
with scores of 28 and above on the BDI-II. The mean score for our PD sample was 8.05, and the
standard deviation was 5.64. In general, about 50% of patients with PD have clinical depression
(Frisina et al., 2008; Raskin et al., 1990).
Mini Mental Status Exam (MMSE). The MMSE (Folstein, Folstein, & McHugh, 1975)
is a 30-question exam administered by an examiner that evaluates general cognitive functioning,
with questions assessing orientation, attention span, learning, memory, and visuospatial
functioning. Scores range from 0 to 30, with a score of 25 and below indicating probable
cognitive impairment (Folstein et al., 1975). The MMSE is a well-established, reliable, and valid
measure, with test-retest reliability levels ranging from r = .83 to .98 depending on patient
population (Folstein et al., 1975). Participants’ scores in each of the groups ranged from 26 to 30
to ensure that cognitive impairment was not a significant factor in this study. For our PD sample,
the mean was 28.80, and the standard deviation was 1.22. In general, about 30% of individuals
with PD are diagnosed with dementia (Raskin et al., 1990; Zgaljardic et al., 2003).
Modified Hoehn and Yahr Stage. The Hoehn and Yahr Scale (Hoehn & Yahr, 1967)
was created to describe parkinsonian symptoms and illness progression and is commonly used in
clinical and research settings. The stages range from 1 to 5, 1 indicating lowest level of
impairment and 5 indicating the highest level of impairment. For this study, the modified Hoehn
and Yahr Scale (Hoehn, 1992) was used and the progression is as follows: 1 = unilateral
impairment only, minimal or no functional impairment; 1.5 = Unilateral and axial involvement; 2
= Bilateral or midline involvement, with no impact on balance; 2.5 = Mild bilateral impairment

33

with recovery on pull test; 3: mild to moderate bilateral impairment with some postural
instability, physical independence; 4 = severe disability, but still able to walk or stand without
assistance; 5 = Mobility only with assistance, wheelchair bound or bedridden. (Goetz et al.,
2004; Hoehn, 1992). For our PD sample, the mean was 2.13 and the standard deviation was 0.67.
Other demographic variables. The other demographic and clinical variables entered
into our prediction analysis include duration of illness (in years), side of initial motor
impairment, education (in years), and age (in years). These variables were gathered through
patient self-report.
Data Analysis
Poser group equivalence assessment. To ensure that there are no significant
demographic differences among the four poser groups, a one-way ANOVA, with Poser Group
(4) as the between-subjects variable will be performed for each of the demographic (gender [1 =
men & 2 = women], age, & years of education) and two of the clinical variables (BDI-II score &
MMSE score). For the PD-specific clinical variables (i.e., Hoehn & Yahr stage and illness
duration [in years]), a one-way ANOVA, with Poser Group (3) as the between-subjects variable,
will be performed for each variable. Main effects will be followed up by the Tukey HSD posthoc test. A chi-square analysis will be done to ensure equivalent gender distribution among the 4
poser groups. Throughout this paper, significant findings (p ≤ .05) and trends (p ≤ .10) will be
reported. Effect sizes will be provided for significant and trend-level main effects and
interactions using partial eta squared (ηp2; Field, 2013). As per Field (2013), for partial eta
squared, a small effect = 0.010 to 0.059, a medium effect = 0.060 to 0.139, and a large effect =
0.140 and above. As needed for data interpretation, trend-level post hoc analyses will be
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followed up by Cohen’s d (d; Cohen, 1992); small effect = 0.20, medium effect = 0.50, and a
large effect = 0.80.
Interrater reliability analyses. Rater cohorts needed to reach an intra-class correlation
(ICC) equal to or greater than .75 during training in order to proceed to rate the experimental
data. ICC analysis on the experimental ratings will be conducted for each facial variable (FM,
EF, EV, EI, & SE) for each rater cohort (i.e., I, II, & III), yielding 15 ICC coefficients.
Aims
Aim 1. We aim to examine facial emotional expression and facial mobility in individuals
with PD versus Healthy Controls using the ratings described above. We hypothesize that all PD
posers (n = 40) will display significantly reduced facial emotional expression (i.e., EF, EV, EI, &
SE) and non-emotional facial mobility (FM) when compared to Healthy Controls.
The statistical approach used to examine this aim will be to conduct a 3-way (2 x 2 x 3)
repeated-measures Analysis of Variance (ANOVA), with Participant Group (PD & HC) and
Gender (Male & Female) as the between-subjects variables and Monologue Type (Happy, Sad,
& Angry) as the within-subject variable. This analysis is evaluating baseline data only in order to
isolate the facial expressivity of PD and HC groups in the absence of treatment effects. This 2 x
2 x 4 ANOVA will be conducted, separately, for each of the facial variables (EF, EV, EI, SE, &
FM). In line with Hypothesis 1, we would expect to find a significant Main Effect for Group,
with the PD group displaying significantly lower emotional expressivity and facial movement
across monologues. If there is support for Hypothesis 2 (i.e., that PD participants display reduced
facial emotional expressivity in the Happy relative to the Sad and Angry monologues), we would
expect significant Group X Emotion interactions. Finally, if there is support for Hypothesis 3,

35

there would be significant main effects of Gender, with women displaying significantly higher
ratings of facial expressivity then men.
Aim 2. We propose to examine changes in facial emotional expression (EF, EV, EI, &
SE) and mobility (FM) over time (from baseline to post-treatment for LSVT & ARTIC groups
and from baseline to 4-5 weeks later for non-treatment groups [i.e., UPDs & HCs]) across the 4
treatment groups. In Hypothesis 4, we predicted that PD patients in the LSVT group would
display significantly more change over time in facial expressivity (EF, EV, EI, & SE) and
mobility than will PD participants with ARTIC treatment, UPDs, and HCs. According to
Hypothesis 5, ARTIC participants would display more improvement in facial expressivity than
will UPDs and HCs but less improvement than LSVT. For Hypothesis 6, we predicted that PD
patients in the LSVT and ARTIC groups would show more improvement over time for negative
than positive monologues.
The statistical approach used to examine Aim 2 was a 4-way (4 x 2 x 2 x 3) repeatedmeasures ANOVA, with Treatment Group (LSVT, ARTIC, UPD, & HC) and Gender (Male &
Female) as the between-subjects variables and Time (Baseline & Post-Treatment) and
Monologue Type (Angry, Happy, & Sad) as within-subjects variables. This 4-way ANOVA was
conducted for each of the five face variables. Results supporting our first and second hypotheses
(i.e., that facial expressivity would be most improved after LSVT, followed by ARTIC) would
show a significant Treatment Group x Time interaction, with LSVT showing the highest levels
of facial expressivity improvement, followed by ARTIC, and with UPDs and HCs showing
lower, yet equivalent, levels of facial change. Results supporting Hypothesis 6 would include a
significant Treatment Group x Time x Monologue interaction, with the LSVT group showing
significantly more facial expressivity improvement for negative (i.e., Sad & Angry) than positive
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(i.e., Happy) and neutral monologues. We predict that participants in the ARTIC group will show
a similar pattern to those in the LSVT group in terms of the Treatment Group x Time x
Monologue interaction.
Aim 3. We proposed to extend the rehabilitation literature by examining whether
demographic (age, gender, & years of education) and clinical (BDI-II, MMSE, Hoehn & Yahr
Stage, illness duration, & side of initial motor symptoms) status can predict facial expressivity
change from LSVT. In Hypothesis 7, we predicted that lower age, Hoehn & Yahr Stage, illness
duration, and BDI-II and that higher years of education and MMSE scores will predict facial
expressivity change over time for LSVT (Hershkovitz & Brill, 2007; Nieuwboer & Weerdt,
2002). We also predicted that individuals with right-sided-onset PD (RPD) would display more
change in facial expression following both rehabilitation treatments than will individuals with
left-sided-onset PD (LPD), based on findings from a subset of these data suggesting that
individuals with RPD show higher levels of facial expressivity than do those with LPD (Bono et
al., 2017), in addition to neuropsychological research regarding right-hemisphere specialization
for facial emotional expression (for reviews, see, for example, Borod, 2000; Borod, Bloom,
Brickman, Nakhutina, & Curko, 2002). The side of motor onset variable is a two point score (1 =
RPD & 2 = LPD).
The statistical approach used to examine this aim was a multiple regression analysis,
which was performed, separately, for each facial expression variable (EF, EI, EV, SE, & FM) for
both the positive and negative emotion monologues for the LSVT Treatment Group. Predictor
variables were the demographic and clinical variables that achieved a significant correlation
(p≤.05) with the particular dependent variable. The dependent variable will be the pre-post
testing change scores (i.e., post-pre) for each of the 5 facial expression variables for the positive
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(i.e., Happy) and negative (i.e., composite score for Angry & Sad) monologues. Before running
the regression analysis, to minimize Type 1 error, we created a composite score for the negative
emotions by calculating the mean of the Angry and Sad ratio change scores for each of the 5
facial variables (i.e., EF, EI, EV, SE, & FM). Next, we correlated each of the 3 demographic and
5 clinical variables with each facial expression variables (i.e., EF, EI, EV, SE, & FM),
separately, for the positive and negative monologues. We included any demographic or clinical
variable that achieved a significant (p ≤ .05) correlation in the multiple regression analysis for
each facial expression change score to which we are predicting.
Results
Preliminary Analyses: Treatment Group Characteristics
Demographic, cognitive, clinical, and affective information for the 4 poser treatment
groups (i.e., LSVT, ARTIC, UPD, & HC) are displayed in Table 1.
The 4 poser groups were carefully matched on demographic variables (i.e., gender, age,
& education [in years]) and on basic cognitive ability (i.e., MMSE score). In addition, the 3 PD
groups were matched on clinical variables (i.e., Hoehn & Yahr disease stage [Hoehn & Yahr,
1967] and duration of illness [in years]). One-way ANOVAs or Chi-square tests comparing the 4
poser groups on demographic and cognitive variables revealed no significant differences for
gender, X2 [3, n = 54] = .15, p = .985; age, F(3, 52) = .38, p = .765; education, F(3, 51) = .53, p =
.662; or MMSE score, F(3, 52) = 1.63, p = .205.
In terms of clinical variables, there were no significant differences among the 3 PD
groups on Hoehn and Yahr stage, F(2, 37) = .327, p = .723 or duration of illness, F(2, 37) = .477,
p = .625. On an exploratory basis and to be comprehensive, the 3 PD poser groups were
compared to each other on the demographic and cognitive variables. There were no significant
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group differences for gender X2 [2, n = 40] = .10, p = .951; age, F(2, 37) = .456, p = .637;
education, F(2, 37) = .031, p = .970; or MMSE, F(2, 37) = .648, p = .529.
In addition, to ensure group equivalence for the Aim 1 analyses, Chi-square tests or
independent-sample t-tests were conducted to compare all of the PDs (n = 40) to the HCs (n =
14). See Table 1 for group means and standard deviations for the demographic and cognitive
variables for all PDs. There were no significant differences between the 2 groups for gender, X2
[1, n = 54] = .05, p = .826; age, t (52) = .475, p = .637; education, t(50)= -1.26, p = .212; or
MMSE score, t(52) = -1.80, p = .078.
Of note, when examining the gender distributions in our sample, there were unequal
numbers of men and women in the PD group, overall (27 vs. 13), and within each of the 3 PD
treatment groups (see Table 1). There were approximately twice as many men as women. Our
data are consistent with the general PD population, where the incidence of PD is reported to be
significantly higher in men than in women (e.g., Van Den Eeden et al., 2003).
Finally, the participant groups were compared on affective functioning, as assessed by the
Beck Depression Inventory, Second Edition (BDI-II; Beck, Steer, & Brown, 1996). When
comparing the 4 poser treatment groups on this variable via ANOVA, there was a significant
main effect of Group, F(3, 52) = 4.92, p = .005. Post-hoc comparisons revealed that the HC
group (M = 3.21, SD = 3.68) obtained significantly lower BDI-II scores than the LSVT (p< .001;
M = 10.50, SD = 6.46) and ARTIC groups (p = .038; M = 7.21, SD = 5.00) but not than the UPD
group (p = .162; M = 5.92, SD = 4.25). None of the other post-hoc comparisons were significant.
Finally, for the Aim 1 analyses, all PDs were compared to the HCs on the BDI-II score. There
was a significant difference, t(52) = 2.98, p = .004, with PDs reporting more depression (M =
8.05; SD = 5.64) than HCs (M = 3.21; SD = 3.68).
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These findings for the BDI-II scores are not surprising in light of previous research
documenting the occurrence of depression in about 40-50% of individuals with PD (for reviews,
see Frisina, Borod, Foldi, & Tennenbaum, 2008; Gotham, Brown, & Marsden, 1988; Raskin,
Borod, & Tweedy, 1990; Zgaljardic, Borod, Foldi, & Mattis, 2003). Due to the significant group
differences for the BDI-II score in our data set and the facts that depression can affect the facial
expression of emotion (e.g., Borod et al., 1990; Jaeger, Borod, & Peselow, 1985) and that flat
affect (e.g., reduced facial expressivity) is a frequent symptom of depression (American
Psychiatric Association, 2013), we decided to control for depression in the Aim 1 and 2 analyses
to follow by covarying for the BDI-II scores.
Rater group characteristics
The raters selected for this study were matched with respect to education and gender such
that an equal number of men and women were in each cohort. The demographic information for
the raters is presented in Table 2.
Inter-rater reliability
We assessed the inter-rater reliability among our raters for each facial variable by
conducting a series of one-way Intra-Class Correlations (ICCs). Four sets of reliability analyses
were conducted. The first two sets were conducted during the training sessions (i.e.,
conferencing and inter-rater reliability stages of training). The third set of reliability analysis was
conducted on the experimental ratings for each cohort, and the final analyses were conducted for
each variable across all 3 cohorts. The results for the training reliability analyses are displayed in
Table 3. The raters had high levels of agreement for their ratings of all five facial variables in all
three cohorts. These results for the experimental reliability analyses are also displayed in Table
3. Raters had high agreement with each other across the facial variables. The inter-rater
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reliability in Cohort 2 for SE and in Cohort 1 for EV are lower than the other ratings, but are still
within the acceptable range.
Aim 1: Assessment of differences between PDs and HCs
In order to assess differences between male and female PDs and HCs, we conducted five
3-way mixed-model ANCOVAs (2 x 2 x 3), with Group (PD & HC) and Gender (Men &
Women) as the between-subjects variables, Emotion (Happy, Sad, & Angry) as the withinsubjects variable, and the BDI-II score as the covariate. We conducted a separate ANCOVA for
each of the five facial variables, including Facial Mobility (FM), Emotional Frequency (EF),
Emotional Variability (EV), Emotional Intensity (EI), and Social Engagement (SE). Results of
these ANCOVAs are displayed in Table 4. To examine significant or trend-level interactions,
post-hoc analyses, using the Hayden-Fisher LSD test (e.g., Williams & Abdi, 2010), were
conducted to compare PDs to HCs.
Hypothesis 1. Contrary to Hypothesis 1, there were no significant or trend-level Main
Effects of Group (PD vs. HC) for any of the facial variables: SE, F(1, 46) = 1.05 p = .311, ηp2 =
.022, β = .171; EF, F(1, 46) = .26, p = .616, ηp2= .006, β = .078; EI, F(1, 46) = .07, p = .793, ηp2=
.002, β = .058; FM, F(1, 46) = 2.16, p = .149, ηp2= .045, β = .301; and EV, F(1, 46) = 1.60, p =
.212, ηp2= .034, β = .236. However, there were significant or trend-level interactions involving
the Poser Group variable that went in the predicted direction for 3 of the 5 facial expression
variables. There was a trend-level Group by Gender interaction for FM, F(1, 46) = 2.96, p =
.092, ηp2= .061, β = .392. (see Figure 1). Post-hoc tests revealed that PD men displayed
significantly lower facial ratings than HC men (p = .008). Contrary to our prediction, there was
no significant difference between PD and HC women (p = .947). Also in line with Hypothesis 1,
there was a significant Group (PD vs. HC) by Emotion (Angry, Happy, & Sad) interaction for
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EV, F(2, 92) = 3.35, p = .040, ηp2= .068, β = .619. When post-hoc tests were conducted
comparing the 2 groups on each of the three emotions, there was a trend with a medium effect
size (p = .068; d = 0.606) for Sad, with PDs lower than Healthy Controls. While the findings for
Angry and Happy were not significant, they were going in the expected direction, with PDs
displaying lower facial expressivity than HCs (see Figure 2). Finally, there was a Group by
Emotion trend for SE, F(2, 92) = 2.95, p = .057, ηp2= .060, β = .562. Although, none of the posthoc comparisons for any emotion was significant or a trend, upon inspection of mean
differences, findings were going in the predicted direction for all 3 emotions, with PDs rated as
less expressive than HCs (see Figure 3). Taken together, while there were no significant main
effects of Poser Group, there were two-way interactions involving the Poser Group variable, with
medium effect sizes for three out of the five facial expressivity variables (i.e., FM, EV, &SE)
that went in the predicted direction (i.e., with PDs displaying lower facial expressivity than HCs
as a function of Gender or Emotion). However, it is notable that power was significantly below
the benchmark for adequate power β = .80, suggesting that there is not enough power in this
analysis to have achieved significant findings with this analysis.
Hypothesis 2. Contrary to our Hypothesis 2 prediction (i.e., that PD participants would
display reduced facial emotional expressivity in positive versus negative monologues), PDs
showed significantly higher expressivity ratings for Happy than for Angry (p = .002) or Sad
monologues (p< .001) for SE (see Figure 5). In a similar vein, for EV, the PDs showed
significantly higher expressivity for Happy than Sad (p = .013). While there was no significant
difference between Angry and Happy for EV, PD ratings were higher for Happy. There were no
significant differences among the emotions for the HCs (see Figure 4).
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Hypothesis 3. As predicted in Hypothesis 3, women were more facially expressive than
were men; this was the case for 4 out of 5 face variables. There was a significant main effect of
Gender for EF, F(1, 46) = 6.31, p = .016, ηp2= .121, β = .691; EI, F(1, 46) = 10.36, p = .002, ηp2
= .184, , β = .883; FM, F(1, 46) = 8.15, p = .006, ηp2= .150, β = .798 ; and EV, F(1, 46) = 9.12, p
= .004, ηp2 = .165, β = .841, with women displaying significantly more facial expressivity than
men (for mean values, see Table 5). These main effects, in two cases, were superseded by
interactions with Emotion. Although there was no significant main effect of Gender for SE, F(1,
46) = 1.17, p = .285, ηp2= .025, β = .185, the data for this variable went in the same direction
with women (M = 3.12, SE = .22) having higher values than men (M = 2.82, SE = .17). There
were also Gender by Emotion interactions for FM, F(2, 92) = 4.94, p = .009, ηp2= .097, β = .797,
and SE, F(2, 92) = 4.24, p = .017, ηp2= .084, β = .730. Post-hoc analyses for FM revealed that
women were significantly (p= .054) more expressive than men for all three emotions (see Figure
6). For SE, there was a trend-level difference (p = .071) for Happy, with women rated as more
expressive than men; post-hoc tests for Angry (p = .484) and Sad were not significant (p = .621),
see Figure 7.
Also of interest is the fact that within a gender group for FM, men showed the highest
level of facial expressivity for Angry (significantly higher than Happy [p = .047] or Sad [p =
.006]) and women showed the highest level of expressivity for Happy (significantly higher than
Angry [p = .029] or Sad [p = .003]; see Figure 8). For SE, men were rated significantly lower for
Sad when compared to Angry (p = .024) or Happy (p = .040), while women, once again, showed
the highest level of expressivity for Happy, which was significantly higher than Angry (p = .009)
or Sad (p< .001); see Figure 9. Further, there were no significant or trend-level interactions for
Group x Gender x Emotion for any of the face variables.

43

In sum, as predicted, there were significant main effects of Gender for four out of the five
facial expressivity variables (i.e., FM, EF, EI, &EV), with women being more expressive than
men. The effect size was large for three of these variables (i.e., FM, EI, & EV) and medium for
EF. Of note, for FM, the main effect was superseded by a significant Gender by Emotion
interaction (medium effect). A significant Gender by Emotion interaction emerged for SE, as
well, with a medium effect size. For both of these interactions, women were significantly more
expressive than men for all three emotions, however, women showed the highest level of
expressivity for Happy and men were most expressive for Angry. The power was in the adequate
range for the majority of main effects and interactions with the Gender variable.
Aim 2: Treatment Effects
To examine Aim 2 and to test Hypotheses 4, 5, and 6, we conducted a series of 4-way (4
x 2 x 2 x 3) repeated-measures ANCOVAs, with Treatment Group (LSVT, ARTIC, UPD, & HC)
and Gender (Men & Women) as between-subjects variables, with Time (Baseline & PostTreatment) and Emotion (Angry, Happy, & Sad) as within-subjects variables, and with the BDIII score as the covariate. The 4-way ANCOVA was conducted, separately, for each of the five
face variables. Significant and trend-level main effects and interactions were examined via posthoc analyses using the Hayden-Fisher LSD test (e.g., Williams & Abdi, 2010). The results of the
5 ANCOVAs are displayed in Table 6.
Hypotheses 4 and 5. For Hypothesis 4, we predicted that LSVT participants would
display increases in facial expressivity from pre- to post-treatment. Our Hypothesis 5 prediction
was that the ARTIC group would also improve facial expressivity from pre- to post-treatment,
yet to a lesser extent than the LSVT group. Consistent with Hypothesis 4, there were significant
or trend-level Group by Time interactions for four out of five face variables: FM, F(3, 46) =
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3.65, p = .020, ηp2 = .207, β = .760; EI, F(3, 46) = 3.30, p = .029, ηp2= .191, β = .712; EF, F(3,
46) = 4.44, p = .043, ηp2 = .175, β = .661; and EV, F(3, 46) = 2.40, p = .082, ηp2 = .146, β = .559
(see Figures 10, 11, 12, & 13). However, please note that three of these interactions (i.e., for FM,
EI, &EV) were superseded by Group by Gender by Time interactions, as well as Group by
Gender by Emotion by Time interactions, which are discussed in the following paragraph. Posthoc analyses revealed that LSVT participants displayed significant improvement from pre- to
post-treatment for FM (p = .019), EI (p = .020), and EF (p = .022). For EV, there was a
borderline trend with a small effect (p = .107; d = 0.167), with LSVT participants rated higher at
post- than pre-treatment. Contrary to the Hypothesis 5 prediction, Hayden-Fisher LSD post- hoc
analyses revealed that ARTIC participants’ facial ratings remained relatively stable over time for
FM (p = .514), EF (p = .281), EI, (p = .343), and EV (p = .225). When the control groups were
examined for these 4 face variables, UPDs displayed a significant decrease over time for FM (p
= .036) and trend-level decreases for EI (p = .085) and EV (p = .104). HC participants’ facial
expressivity ratings remained stable over time for each of the four variables discussed above
(i.e., FM [p = .907], EF [p = .682], EI [p = .851], & EV [p = .839]). Finally, for SE, the Group by
Time interaction was not significant, F(3, 46) = .16, p = .925, ηp2= .011, β = .076.
There were also significant Group by Gender by Time interactions for FM, F(3, 46) =
2.90, p = .046, ηp2= .172, β = .650; EI, F(3, 46) = 4.09, p = .012, ηp2 = .226, β = .810; and EV,
F(3, 46) = 3.54, p = .023,ηp2= .202, β = .746, suggesting that the treatment effect for these
variables was moderated by Gender (see Figures 14, 15, & 16). For FM, post-hoc tests revealed
significant improvement with a small effect size (p = .052; d = 0.307) from pre- to post-treatment
for LSVT men and a trend-level change with a small effect size (p = .071; d = 0.427) in the same
direction for LSVT women. For EI, post-hoc analyses showed trend-level increases with small
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effect sizes for both LSVT men (p = .082; d = 0.336) and LSVT women (p = .062; d = 0.120)
from pre- to post-treatment. For EV, LSVT men displayed significant change (p = .046) over
time, but the change for women was not significant (p = .359; d = 0.169). Contrary to our
Hypothesis 5 prediction, ARTIC participants’ facial ratings from pre- to post-treatment were
either stable (i.e., for FM men [p = .385], FM women [p = .128], EV men [p = .539], & EI men
[p = .347]) or significantly decreased (i.e., EV women [p = .043] & EI women [p = .052]). In
addition, UPD women showed significant decreases in facial expressivity from pre- to posttreatment for EV (p = .040), FM (p = .017), and EI (p = .018). The facial ratings for UPD men
and HC participants (i.e., both men & women) for EV, FM and EI remained stable over time.
Finally, no 3-way Group by Gender by Time interactions emerged for EF, F(3, 46) = 1.63, p =
.197, ηp2 =.104,β = .396 or SE, F(3, 46) = .65, p = .590, ηp2= .044, β = .174.
In sum, significant or trend-level Group by Time interactions with large effect sizes
emerged for four out of the five facial expressivity variables (i.e., FM, EF, EI, and EV), showing
that individuals in the LSVT improved significantly more than the other three groups. However,
for FM, EI, and EV, these two-way interactions were superseded by 3-way Group by Gender by
Time interactions, each of which also had large effect sizes. Post-hoc analyses revealed that both
men and women in the LSVT groups showed significant or trend-level improvements following
treatment for both FM and EI (small effect sizes), but that only LSVT men showed significant
improvements for EV. For the ARTIC and UPD groups, women displayed significant decreases
for multiple variables whereas men in both groups were stable over time. HCs were also stable
over time. The power ranged from β = .559 to β = .810 for the significant and trend-level twoand three-way interactions, suggesting that there may not have been adequate power to detect
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significant results for the trend-level findings. Furthermore, the two- and three-way interactions
for SE were significantly below the benchmark for adequate power.
Hypothesis 6. Consistent with our Hypothesis 6 prediction (i.e., that individuals in the
LSVT group would increase more from pre- to post-treatment for the negative monologues [i.e.,
Angry and Sad] than for the positive monologue [i.e., Happy]), there were significant or trendlevel 4-way Group by Gender by Time by Emotion interactions for FM, F(6, 84) = 2.19, p =
.053, ηp2 = .135, β = .747; EF, F(6, 84) = 1.91, p = .089, ηp2= .120, β = .676; and EI, F(6, 84) =
1.83, p = .103, ηp2 = .116, β = .654(see Tables 7, 8, & 9). Post-hoc analyses showed a significant
increase from pre- to-post-treatment for LSVT women for the Sad monologue for FM (p = .004),
EF (p = .004), and EI (p = .007). There were also significant or trend-level increases for LSVT
men for the Happy monologue for FM with a small effect size (p = .096; d = 0.347) and EF (p =
.050). Contrary to our prediction for the ARTIC group, post-hoc analyses showed that ARTIC
women exhibited significant decreases from pre- to post-treatment for the Sad monologue for
FM (p = .026), EF (p = .012), and EI (p = .022), but stable ratings over time for both Angry and
Happy. No significant differences from pre- to post-treatment were seen for men in the ARTIC
group. In addition, for the UPD group, women showed significant decreases over time for FM
Angry (p = .048), FM Happy (p = .027), and EI Angry (p = .042). There were no significant
changes in facial expressivity over time for UPD men or for HC participants (i.e., men &
women) for any of the emotions.
Taken together, there were significant and trend-level Group by Gender by Emotion by
Time interactions for FM, EF, and EI, all with medium effect sizes, all of which supersede the 2and 3-way interactions discussed in the preceding paragraphs. Overall, in these interactions,
post-hoc analyses revealed that significant increases following LSVT occurred for women for
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Sad and for men for Happy. Women in both the ARTIC and UPD groups displayed significant
decreases in facial expressivity for multiple face variables whereas men were stable. HCs were
also stable over time. Of note, the power for all of these analyses was below the adequate level.
Aim 3: Predictive Analysis
In order to examine this aim, we conducted a multiple regression analysis, separately, for
each facial expression variable (EF, EI, EV, SE, & FM) for both the positive (i.e., Happy) and
negative (i.e., mean score of Sad & Angry) emotion monologues for the LSVT treatment group.
Predictor variables were the demographic and clinical variables that achieved a significant
correlation (p ≤ .05) with one or more of the dependent variables (i.e., Gender, Illness Duration,
MMSE score, & BDI-II score; see Table 10). The dependent variables were the pre-post testing
change scores (i.e., the post score minus the pre score) for each of the 5 face variables for the
positive and negative monologues.
For the preliminary correlations, there were significant Pearson Product-Moment
correlations between the BDI-II score and the following LSVT baseline scores: FM Negative, r =
.67, p = .017; FM Positive, r = .63, p = .029; and EV Positive, r = .60, p = .040. There were also
significant correlations between Gender and the following face variables: FM Negative, r = .72,
p = .005; EV Negative, r = .55, p = .050; FM Positive, r = .71, p = .007; EF Positive, r = .55, p =
.051; and EV Positive, r = .62, p = .026. Significant correlations also emerged between the
MMSE score and SE Positive, r = -.61, p = .037 and between Illness Duration and FM Positive, r
= .63, p = .030 (see Table 10). Therefore, for the regression analyses to follow, we used Gender,
Illness Duration, MMSE score, and BDI-II score as the predictor variables.
Hypothesis 7. For Hypothesis 7, we predicted that lower Illness Duration and BDI-II
scores and that higher MMSE scores would predict facial expressivity improvement in LSVT
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participants. We also predicted that female participants would show more facial improvement
following LSVT than would male participants. Contrary to these predictions, none of the
multiple regression analyses involving 4 predictor variables yielded significant results for any of
the 10 face variables (i.e., Positive & Negative Emotion X 5 face variables; see Table 11).
However, there was one trend-level finding for SE Positive Emotion, Multiple R = .81, R2 = .66,
p = .077, with Gender (t = -2.42, p = .046; men changing more), BDI-II score (t = 2.37, p = .050;
individuals with higher levels of depression changing more), and MMSE (t = 1.93, p = .094;
individuals with higher cognitive functioning changing more) making significant or trend-level
contributions to the analysis (see Table 12).
Discussion
This dissertation examined differences in facial mobility and expression between PD and
HC individuals as well as the impact of a voice treatment (i.e., LSVT) on facial change in PD.
Lastly, in order to extend the rehabilitation literature, we examined the impact of demographic
and clinical factors in predicting facial change through LSVT.
Aim 1, Hypothesis 1: Facial Expression, PD versus HC Participants
In Aim 1, we hypothesized that individuals with PD would display significantly reduced
facial mobility and emotional expression relative to healthy controls. Our findings were
somewhat consistent with this expectation, revealing significantly lower facial mobility (FM)
and emotional variability (EV) for the PD participants as compared to HCs. However, these
effects were moderated by emotion and gender. For FM, PD men displayed significantly lower
facial ratings than HC men, while there were no significant group differences for women on this
variable. This finding is in line with gender differences in the clinical presentation of PD
(Haaxma et al., 2007), such that more women initially present with tremor, whereas men present
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with bradykinesia or rigidity. According to these authors, symptoms of bradykinesia and rigidity
affect the face whereas tremor affects the extremities. For EV, PDs presented with significantly
lower expressivity than HCs for the Sad monologue, but there were no significant group
differences for Happy or Angry monologues. Also, for social engagement (SE), there was a trend
with a medium effect size for the Group by Emotion interaction. Although none of the post-hoc
comparisons were significant, the findings were going in the predicted direction, with PDs rated
as less expressive than HCs for all three emotions. The findings for Social Engagement are of
interest, as, instead of focusing on individual aspects of facial expression and movement, the SE
variable is a subjective rating of how engaged, attentive, connected, or involved the individual
appears. Importantly, individuals with PD have difficulties in social situations and have been
reported to have communication problems and difficulties in interpersonal interactions (e.g.,
Coker & Burgoon, 1987; Riggio & Friedman, 1986; Spielman et al., 2003). Overall, the findings
for FM and EV are consistent with the literature, where evidence of reduced facial expression
and mobility in PD has been previously observed (Borod et al., 1989; Buck & Duffy, 1980;
Dumer et al., 2014; Katsikitis & Pilowsky, 1988, 1991; Simons et al., 2004; Smith et al., 1996;
for reviews, see Bono & Borod, 2016; Halfacre et al., 2009).
Aim 1, Hypothesis 2: The Effect of Emotional Valence on Facial Expression
Contrary to our prediction and the literature documenting more impairment in PD for
positive than negative emotional expressions (e.g., McCabe, 2013; McCabe et al., 2016; Pitcairn
et al., 1990), individuals with PD displayed significantly higher EV and SE (medium effect size)
while producing positive (i.e., Happy) than negative (i.e., Angry & Sad) emotion monologues.
There were no significant or trend-level Group by Emotion interactions for the three other face
variables. It is possible that individuals with PD are evaluated by naïve observers as being
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impaired across all emotions and that it is difficult to recognize the impairment among discrete
emotions without facial action coding experience (e.g., FACS; Ekman & Friesen, 1978), which
has been used for facial expressivity analysis in the studies citing this difference (McCabe, 2013;
Pitcairn et al., 1990). Given that our findings have a medium effect size, it brings into question
the literature suggesting that PDs are more expressive for negative than positive emotions. In
fact, consistent with the current study, a study by Borod et al., (1990) found that PDs produced
positive facial expressions with more emotional intensity than negative expressions.
Aim 1, Hypothesis 3: The Effect of Gender on Facial Expression
As predicted, women displayed significantly more facial emotional expressivity (i.e., EF,
EV, & EI) and facial mobility (FM) than did men, consistent with the extensive facial literature
on gender differences in facial emotional expression (for reviews, see Borod & Madigan, 2000;
Hall & Matsumoto, 2004; Huang & Hu, 2009; Scholten, Aleman, Montagne, & Kahan, 2005;
Thayer & Johnson, 2000). Although there were no significant differences between men and
women for the Social Engagement variable, the findings went in the same direction, with women
were being rated as more expressive than men.
Although women were found to be more expressive than men across the facial variables,
these findings were modified by Gender by Monologue Type interactions for FM and SE. For
these variables, women were most expressive for Happiness and men were most expressive for
Anger. This is in line with related evidence from the healthy adult literature, indicating that
women smile more frequently than men (LaFrance, Hecht, & Paluck, 2003) and that women
experience more negative social consequences for displaying anger than do men (e.g., Brescoll &
Uhlmann, 2008). Our findings are also consistent with the neuropsychology of emotion
literature, which suggests that women are more lateralized for positive emotions, whereas men
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are more lateralized for negative emotions (Borod & Caron, 1980). Lastly, evidence from
developmental psychology suggests that girls are better at concealing negative emotions than are
boys (Davis, 1995), possibly due to the negative social consequences women experience for
displaying anger (e.g., Brescoll & Uhlmann, 2008). It is possible that some of our women
participants felt uncomfortable expressing intense emotion regarding negative events due to
cultural attitudes.
Aim 2, Hypothesis 4: The Effect of LSVT on Facial Expression
For Hypothesis 4, we predicted that PDs in the Lee Silverman Voice Treatment (LSVT)
group would display significantly more improvement in facial mobility (FM), emotional
frequency (EF), emotional variability (EV), emotional intensity (EI), and social engagement (SE)
from pre-to-post treatment than would the Articulation (ARTIC), Untreated PD (UPD), and
healthy control (HC) groups. Our findings supported this hypothesis, with significant or trendlevel improvements with large effect sizes for the LSVT group for four out of the five face
variables (i.e., FM, EF, EV, & EI). However, for EV, this interaction was moderated by Gender,
with significant increases from pre- to post-treatment for men but no significant difference for
women in the LSVT group.
These results, coupled with the large effect size, are consistent with earlier studies
suggesting that LSVT improves facial expressivity (Alterescu et al., 2013; Halfacre et al., 2016;
Spielman et al., 2003). Our findings are particularly important since there are few empirically
validated treatments targeting facial expression and mobility in individuals with PD. Although
the physical and occupational therapy literature reports (e.g., Dixon et al., 2007; Gauthier,
Dalziel, & Gauthier, 1987) targeting facial expression as a part of a holistic treatment plan for
individuals with Parkinson’s disease, there is limited empirical support documenting their
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specific effectiveness for face, as many of the studies are evaluating treatment effectiveness
through an aggregate score of motor symptomology (of which facial expressivity is a
component), making it difficult to parse out the extent to which these interventions are
improving facial expressivity. To our knowledge, there have only been two other studies
specifically carried out to attempt to improve facial mobility and facial expressivity in
Parkinson’s disease, one using orofacial physiotherapy (Katsikitis & Pilowsky, 1996) and the
other using the active music therapy technique (Elefant, Lotan, Baker, & Skeie, 2012). However,
the empirical support for each of these approaches is also quite limited (i.e., one article per
approach). In fact, the majority of empirically supported treatments targeting the face were
created for individuals with facial palsy, including video self-modeling (e.g., Coulson, Adams,
O’Dwyer, & Croxson, 2006), mime therapy (e.g., Devriese & Bronk, 1977; Beurskens &
Heymans, 2004, 2006), and facial neuromuscular re-education approach (e.g., Cronin &
Steenerson, 2003; Lindsay, Robinson, & Hadlock, 2010; Nakamura, Toda, Sakamaki, Kashima,
& Takeda, 2003; Pourmomeny, Zadmehre, Mirshamsi, & Mahmodi, 2014; Ross, Nedzelski, &
McLean, 1991). Unfortunately, none of these treatments are validated approaches for individuals
with PD.
Our treatment effect findings also provide support for the theory about an integrated
system of emotion (Borod, 1993b; Kaiser & Scherer, 1998; Porges, 2001), which suggests that
various communication channels (e.g., facial & vocal/prosodic) work together when producing
an emotional response. Our findings also support the overlap in neural pathways between facial
and vocal systems (i.e., for both systems, posed expression is mediated via neocortical pathways
whereas spontaneous expression is mediated by subcortical and limbic pathways; for reviews,
see Bono & Borod, 2016; Borod, 1993a; Borod & Koff, 1984), as well as the overlap in neural
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structures regulating facial and vocal expression (i.e., anterior cingulate cortex, peraqueductal
grey, thalamus, & basal ganglia; Devinsky, Morrell, & Vogt, 1995; Jurgent & Zwirner, 1996).
Another theory regarding LSVT treatment mechanisms involves the neurotransmitter dopamine.
Dopamine is the primary neurotransmitter impacted by PD and has a well-supported history of
being associated with reward systems and goal- directed behavior (e.g., De la Fuente-Fernandez,
Ruth, Sossi, Schulzer, Calne, & Stoessl, 2001; De la Fuente-Fernandez & Stoessl, 2002).
Songbirds have been used as an animal model to study speech production due to the similarities
between human speech and bird song. Findings from these studies suggest that basal ganglia
circuits in songbirds and humans are similar in that dopaminergic functions appears to be critical
for goal-directed changes in both speech and song output (Heimovics & Riters, 2008; Simonyan,
Horwitz, & Jarvis, 2012). In this context, it is possible that engaging in an intensive vocal-based
treatment may have an impact on the dopaminergic system, thereby exerting influence on motor
symptoms in PD. In addition, it is possible that the social component involved in completing an
intensive treatment may have reduced symptoms of depression, thereby improving facial
expressivity. Indeed, recent studies with PD patients suggest that the expectation of symptom
improvement may activate endogenous dopamine in the striatum, which may actually influence
motor symptoms (e.g., Miwa, 2007).
The differential effects of LSVT as a function of Gender, with men improving more than
women overall, were unexpected. However, it is interesting that this finding is consistent with
gender differences in PD symptomology, such that men are more likely to present initially with
motor symptoms of bradykinesia and rigidity, which are more likely to impact the face (Haaxma
et al., 2007), and report more motor symptoms over the course of the disease than do women
(Scott, Borgman, Engler, Johnels, & Aquilonius, 2000). It is possible that men treated with
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LSVT showed more change than women because they present with more facial expressivity
impairment at baseline, and may, therefore, be showing more visible change post treatment.
Indeed, in our dataset, for facial mobility, PD men displayed significantly lower facial ratings
than HC men, while there were no significant group differences for women. Another theory is
that women with PD may be more conscious of their reduced facial expressivity and might
overcompensate due to the social consequences associated with facial expressivity deficits (e.g.,
Hemmesch, Tickle-Degnen, & Zebrowitz, 2009).
Aim 2, Hypothesis 5: The Effect of ARTIC on Facial Expression
Our fifth hypothesis was that FM, EF, EV, EI, and SE would also improve following
ARTIC treatment, but to a lesser degree than after LSVT. Contrary to our expectation, there was
no significant improvement in facial expressivity or mobility from pre- to post-treatment
following ARTIC, regardless of large effect sizes. Though the power was variable for the
different analyses, closer inspection of the means revealed stable performance. For the most part,
the PD participants treated with ARTIC were stable over time, and, actually, significant
decreases in expressivity were seen for EV and EI among female PDs. It is possible that ARTIC
did not exert as much influence over facial expressivity and mobility as LSVT because ARTIC
targets higher level components of speech production (i.e., articulation), which involve more
neocortical than subcortical control (e.g., Dronkers, 1996; Hillis, Work, Barker, Jacobs, Breese,
& Maurer, 2004). By comparison, LSVT targets more primitive aspects of vocal production
(e.g., respiration & phonation), exerting its influence on older phylogenetic brain regions (e.g.,
subcortical areas), which are more involved in emotional processing and are more affected in PD
(e.g., Jurgens, 2002). Relative to LSVT, ARTIC is not an effective treatment to increase facial
expressivity and mobility in PD.
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Aim 2, Hypothesis 6: Differential Effects of LSVT on Facial Emotional Expression for
Positive versus Negative Emotion
Consistent with our Hypothesis 6 prediction (i.e., that individuals in the LSVT group
would increase more from pre- to post-treatment for negative [Angry & Sad] than positive
monologues [Happy]), there were significant or trend-level Group by Gender by Time by
Emotion interactions with medium effect sizes for three out of five face variables (i.e., FM, EF,
& EI), with LSVT women showing significant increases in facial expressivity from pre- to posttreatment for the Sad monologue. By contrast, ratings remained stable ratings over time for the
Angry and Happy monologues for LSVT women. This is consistent with the literature suggesting
that individuals with PD are more expressive for negative than positive emotions (e.g., Brozgold
et al., 1998; McCabe, 2013; Pitcairn et al., 1990). Though there are no studies, to our knowledge,
specifically exploring gender differences in facial emotional expressivity in PD, the gender
literature shows that women use more facial muscle movements when expressing negative
emotions than do men (Schwartz, Brown, & Ahern, 1980). By contrast, LSVT men showed a
significant or trend-level increase over time in EF and FM for the Happy monologue but no
change for the Angry and Sad monologues. In addition, ARTIC women exhibited significant
decreases (large effect) from pre- to post-treatment for Sad for all three variables (i.e., FM, EF,
& EI) but stable ratings for both Angry and Happy. UPD women showed significant decreases
over time for FM Angry, FM Happy, and EI Angry but stable ratings for all other monologues
and face variables. The findings for ARTIC and UPDs suggest that the impact of ARTIC on
facial expressivity is minimal. No significant differences from pre- to post-treatment were seen
for ARTIC men, UPD men, HC men, or HC women. Because of the unequivocal findings with
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respect to emotional valence, future work in this area should utilize a larger number of both
positive and negative emotions.
Aim 3, Hypothesis 7: Predictive Analysis for LSVT
When the multiple regression findings were examined for each of the facial variables,
there was only one trend-level finding (i.e., for SE Positive), with Gender (men changing more
over time), BDI-II score (individuals with higher levels of depression changing more), and
MMSE (individuals with higher cognitive functioning changing more) making significant or
trend-level contributions to the analysis. Contrary to our predictions, demographic and clinical
factors only made contributions to one of the facial expressivity variables, which may be due to
low power due to our small sample size. As such, it is possible that the overall finding for SE
Positive may have some important clinical implications, since some of the specific findings were
consistent with the rehabilitation literature. One of these findings includes the influence of
cognitive status on rehabilitation treatments. In our study, the individuals in the LSVT group
with higher overall cognitive functioning showed more facial expressivity improvement,
consistent with previous literature examining the impact of cognitive status on treatment
outcomes (Fusco et al., 2009; Hershkovitz, Gottlieb, Beloosesky, & Brill, 2006; Landi et al.,
2002). Contrary to prior research (Fusco et al., 2009), we found that individuals with higher
levels of depression increased their facial expressivity following treatment. As depression has a
documented impact on facial expression (e.g., Borod et al., 1990; Jaeger, Borod, & Peselow,
1985), it is likely that individuals who were more depressed displayed less facial affect at the
start of treatment and may have, therefore, showed more visible change from pre- to posttreatment. In terms of Gender, our data for SE positive showed that LSVT men changed more
over time than LSVT women. Although there were no specific predictions for Gender with
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respect to treatment, similar to what was noted in the Introduction, it is possible that women, in
general, are more conscious of reduced facial expressivity than are men and that they
overcompensate due to the social consequences associated with facial expressivity deficits (e.g.,
Brozgold et al., 1998), particularly for women in our western societies (e.g., Hemmesch, TickleDegnen, & Zebrowitz, 2009).
Study Limitations
A limitation of this study, as well as many studies exploring facial expression in PD, is
the effect of depression on facial expression. Due to the high comorbidity of depression and PD,
individuals with severe depression were excluded from this study. The BDI-II was used as a
screening measure for poser participants; only participants with a score of 28 or lower were
included in the study. In addition, we covaried for the BDI-II in our data analyses in order to
statistically control for the possible effects of depression symptomology on each poser’s facial
expressivity scores.
Another limitation of this study is that the medication status of the PD participants was
not a factor in our analyses. It is possible that medication type, dosage, and side effects may have
affected the facial movement and expressivity of our PD participants. Future studies
investigating facial expression in PD should account for this variable.
The composition of our sample is another limitation of this study. All participants were
from the Boulder/Denver, Colorado area, and most were of Caucasian descent (i.e., 96.3%; 3.7%
Hispanic) and well-educated. These findings may not be generalizable to other ethnic and lesseducated groups. Future research with more culturally diverse samples is warranted. In addition,
the sample size in the current study was relatively small, and, to increase the power, future
studies should use larger numbers of participants.
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Another potential limitation of our study is the type of facial rating system that was used.
Although our raters were trained to high levels of interrater reliability, the ratings are subjective.
There are systems that more objectively evaluate facial expression (i.e., FACS [Ekman &
Friesen, 1978] & MAX [Izard, 1979]). However, of note, there was a study done with a
component of the current dataset using FACS, which also found a significant effect of LSVT on
facial expressivity (Dumer, 2011; Dumer et al., 2014).
Future Directions
One suggestion for future studies is to investigate the relationship between social
engagement and facial expressivity in order to determine whether facial expressivity (i.e., EF,
EV, & EI) contributes to being an engaging social partner. In a similar vein, the relationship
between facial mobility and emotional expressivity could be examined and mobility controlled
for when analyzing the measures of emotional expression. Future research suggestions specific
to LSVT include exploring the impact of PD medication on facial and vocal change following
LSVT as well as investigating the perceptions of facial improvement via LSVT by family
members and healthcare workers. It would also be interesting to directly investigate the impact
of LSVT on quality of life and interpersonal relationships. Lastly, neuroimaging studies would
be useful to investigate the proposed neural mechanisms involved in LSVT, and to lend further
support to the integrated theory of emotional expression.
Clinical Implications
There are multiple clinical implications that this study has for the PD and rehabilitation
literature. Facial expression is examined through a multifactorial approach, involving mobility,
expressivity, and social judgment of others, which has not been carried out in other studies with
PD. In terms of treatment, our findings for LSVT are important to the rehabilitation therapy
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literature because there are few empirically validated treatments targeting facial emotional
expression and mobility for individuals with PD. Though earlier studies using a subset of these
data have examined the impact of LSVT on facial expression, the differential effect of LSVT on
emotional valence was not previously examined, and none of the earlier studies examined the
effect of demographic, clinical, cognitive, and affective variables on facial emotional expression
improvement through LSVT.
Conclusions
Parkinson’s disease is associated with a wide range of motoric, cognitive, and affective
symptoms. Impairments in facial mobility and emotional expressivity are common and can
impair communication, in turn, affecting daily functioning and quality of life. We found that
individuals with PD were less facially expressive than healthy adult participants, though these
findings were influenced by gender and emotion type. We also found that LSVT, a rehabilitation
therapy initially created to improve vocal loudness, is also an effective treatment for facial
expressivity. Contrary to our expectations, demographic, clinical, cognitive, and affective
variables did not lead to significant improvements in LSVT, likely due to small sample size and
low power.
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Table 1
Demographic, Clinical, Cognitive, and Affective Characteristics for Poser Participant Groups
Groups

LSVT
(n = 13)

ARTIC
(n = 14)

UPD
(n = 13)

All PD
(n = 40)

HC
(n = 14)

Gender

M (n = 9)
W (n = 4)

M (n = 9)
W (n = 5)

M (n = 9)
W (n = 4)

M (n = 27)
W (n = 13)

M (n = 9)
W (n = 5)

66.7 (6.6)

68.4 (10.2)

65.3 (8.8)

66.8 (8.5)

65.5 (8.3)

Education
(in years)
M (SD)

16.3 (2.8)

16.6 (4.3)

16.4 (2.7)

16.4 (3.2)

17.7 (2.8)

Hoehn & Yahr
Stage
M (SD)

2.2 (0.5)

2.2 (0.9)

2.0 (0.5)

2.1 (.7)

----------

Illness
Duration
(in years)
M (SD)

6.0 (8.3)

3.8 (3.2)

5.5 (4.5)

5.0 (5.5)

Side of Initial
Motor Symptom

RPD (n = 6)
LPD (n = 5)
UN (n = 2)

RPD (n = 5)
LPD (n = 7)
UN (n = 2)

RPD (n = 4)
LPD (n = 8)
UN (n = 1)

RPD (n = 15)
LPD (n = 20)
UN (n = 5)

----------

BDI-II Score
M (SD)

10.5 (6.5)

7.2 (5.0)

5.9 (4.3)

8.1 (5.6)

3.2(3.7)

MMSE Score
M (SD)

28.8 (1.6)

28.5 (1.2)

29.0 (0.8)

28.8 (1.2)

29.4 (0.7)

Age
M (SD)

----------

Note. LSVT=Lee Silverman Voice Treatment; ARTIC=Articulation Treatment; UPD=Untreated Parkinson’s
disease; All PD=All Parkinson’s disease participants; HC=Healthy Controls; RPD=right-sided PD onset;
LPD=left-sided PD onset; UN=unknown PD onset; BDI-II=Beck Depression Inventory, 2nd edition; MMSE=Mini
Mental Status Exam
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Table 2
Demographic Characteristics of Rater Participants

Cohort

Gender
(% Women)

Age
M (SD)

Education in Years
M (SD)

Cohort 1 (n = 6)
Cohort 2 (n = 6)
Cohort 3 (n = 6)

50%
50%
50%

25.3 (6.15)
23.8 (2.03)
23.8 (6.59)

15.5 (0.55)
16.3 (0.75)
14.5 (1.50)
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Table 3
Intra-class Correlations for Training Sessions: Conferencing, Inter-rater Reliability, and
Experimental Rating Data
FM

Training Variables
EF
EI

EV

SE

Cohort 1

Conferencing
Inter-rater Reliability
Experimental Rating Data

.962
.921
.812

.918
.910
.836

.976
.937
.849

.902
.848
.694

.984
.926
.841

.932
.860
.896

.943
.883
.847

.923
.924
.731

.895
.893
.767

.948
.863
.696

.948
.908
.867

.946
.875
.757

.953
.910
.885

.903
.883
.867

.901
.946
.815

Cohort 2

Conferencing
Inter-rater Reliability
Experimental Rating Data
Cohort 3

Conferencing
Inter-rater Reliability
Experimental Rating Data

Note. FM = Facial Mobility; EF = Emotional Frequency; EV = Emotional Variability; EI = Emotional Intensity;
SE = Social Engagement.
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Table 4
Aim 1: Poser Group by Gender by Emotion ANCOVA (2 x 2 x 3), Significance of Effects (pvalues)

Effect

Facial Rating Variable
FM

Group

Gender
Emotion
Group X Gender
Group X Emotion
Gender X Emotion
Group X Gender X Emotion

.149
.006*
.006*
.092†
.343
.009*
.355

EF

EV

.616
.016*
.030*
.315
.795
.232
.997

.212
.004*
.010*
.317
.040*
.201
.157

EI

SE

.793
.002*
.029*
.297
.659
.406
.959

.311
.285
.000*
.375
.057†
.017*
.690

Note.
1
FM = Facial Mobility; EF = Emotional Frequency; EV = Emotional Variability; EI = Emotional Intensity;
SE = Social Engagement.
2
BDI-II score was used as a covariate in this analysis
3
**p≤.01; *p≤.05; †p≤.10
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Table 5
Aim 1: Means for the Main Effect of Gender

FM (p = .006)
Gender Men Women
Mean
2.62 3.37
(SD)
(.16) (.21)

EF (p = .016)
Men
2.54
(.19)

Women
3.36
(.26)

EV (p = .004)
Men
2.16
(.14)

Women
2.86
(.19)

EI (p = .002)
Men
2.18
(.17)

SE (p = .285)

Women Men
3.10
2.82
(.23)
(.17)

Women
3.12
(.22)

Note. FM = Facial Mobility; EF = Emotional Frequency; EV = Emotional Variability; EI = Emotional Intensity; SE
= Social Engagement.
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Table 6
Aim 2: Poser Group by Gender by Time by Emotion ANCOVA (4 x 2 x 3 x 3), Significance of
Effects (p-values)

Effect
Poser Group
Gender
Time
Emotion
Poser Group x Gender
Poser Group x Time
Poser Group x Emotion
Gender x Time
Gender x Emotion
Time x Emotion
Poser Group x Gender x Time
Poser Group x Gender x Emotion
Poser Group x Time x Emotion
Gender x Time x Emotion
Poser Group x Gender x Time x Emotion

Facial Rating Variable
FM

EF

EV

EI

SE

.168
.000*
.166
.000*
.545
.020*
.485
.412
.015*
.729
.046*
.878
.462
.119
.052*

.265
.004*
.055†
.004*
.513
.043*
.903
.957
.104
.959
.197
.988
.311
.102
.089†

.158
.001*
.395
.000*
.710
.082†
.071†
.274
.032*
.275
.023*
.203
.653
.221
.125

.361
.001*
.144
.054*
.726
.029*
.779
.322
.136
.636
.012*
.976
.354
.081†
.103†

.193
.236
.692
.000*
.770
.925
.013*
.473
.008*
.960
.590
.195
.409
.545
.212

Note.
1
FM = Facial Mobility; EF = Emotional Frequency; EV = Emotional Variability; EI = Emotional Intensity;
SE = Social Engagement.
2
BDI-II score was used as a covariate in this analysis
3
**p≤.01; *p≤.05; †p≤.10
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Table 7
Aim 2: Means and Standard Deviations for the Poser Group by Gender by Time by Emotion
Interaction for FM (p = .052)
Group
LSVT
Emotion
Angry
Happy
Sad
Time
Pre
Post
Pre
Post
Pre
Post
Men
1.95 (.26)
2.18 (.25)
1.91 (.29)
2.19 (.24)
1.80 (.28)
1.99 (.25)
Women
3.24 (.57)
3.22 (.55)
3.17 (.63)
3.61 (.53)
2.59 (.62)
3.58 (.56)
Group
Emotion
Time
Men
Women
Group
Emotion
Time
Men
Women
Group
Emotion
Time
Men
Women

ARTIC
Happy

Angry
Pre
2.21 (.28)
3.01 (.35)

Post
2.22 (.27)
2.97 (.33)

Pre
2.21 (.31)
3.31 (.38)

Post
2.66 (.25)
3.27 (.43)

Pre
2.62 (.29)
4.31 (.49)

Post
3.13 (.27)
3.49 (.34)

Pre
2.97 (.31)
3.63 (.39)

Pre
1.92 (.30)
3.11 (.37)

Post
2.11 (.27)
2.66 (.34)

Sad
Post
2.55 (.24)
3.67 (.41)

Pre
2.44 (.28)
3.69 (.48)

Post
3.02 (.26)
3.52 (.33)

Sad
Pre
Post
3.06 (.30)
2.85 (.27)
3.28 (.38)
3.52 (.35)

HC
Happy

Angry
Pre
3.33 (.28)
3.33 (.36)

Post
2.34 (.26)
3.10 (.32)

UPD
Happy

Angry
Pre
2.47 (.26)
3.85 (.45)

Sad

Post
2.31 (.26)
3.42 (.44)

Note. LSVT=Lee Silverman Voice Treatment; ARTIC=Articulation Treatment; UPD=Untreated Parkinson’s
disease; All PD=All Parkinson’s disease participants; HC=Healthy Controls.
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Table 8
Aim 2: Means and Standard Deviations for the Poser Group by Gender by Time by Emotion
Interaction for EF (p = .089)
Group
LSVT
Emotion
Angry
Happy
Sad
Time
Pre
Post
Pre
Post
Pre
Post
Men
1.96 (.34)
2.20 (.31)
1.95 (.34)
2.41 (.32)
1.99 (.39) 2.05 (.27)
Women
2.27 (.75)
2.46 (.68)
2.73 (.75)
2.81 (.71)
1.61 (.85) 3.11 (.60)
Group
Emotion
Time
Men
Women
Group
Emotion
Time
Men
Women
Group
Emotion
Time
Men
Women

Angry
Pre
Post
2.58 (.36)
2.39 (.33)
3.23 (.45)
3.17 (.41)

ARTIC
Happy
Pre
2.52 (.37)
3.53 (.45)

Sad
Pre
Post
2.23 (.42) 2.22 (.29)
3.59 (.52) 2.81 (.36)

Post
2.57 (.33)
4.08 (.56)

Sad
Pre
Post
2.38 (.39) 2.15 (.28)
3.85 (.67) 3.98 (.47)

Post
2.89 (.35)
3.77 (.45)

Sad
Pre
Post
2.98 (.41) 2.70 (.29)
3.38 (.53) 3.57 (.37)

UPD
Happy

Angry
Pre
2.36 (.34)
3.96 (.58)

Post
2.70 (.35)
3.58 (.43)

Post
2.57 (.31)
3.49 (.53)

Angry
Pre
Post
2.96 (.36)
2.93 (.33)
3.25 (.47)
3.46 (.43)

Pre
2.49 (.34)
4.70 (.58)
HC
Happy
Pre
2.85 (.36)
3.57 (.47)

Note. LSVT=Lee Silverman Voice Treatment; ARTIC=Articulation Treatment; UPD=Untreated Parkinson’s
disease; All PD=All Parkinson’s disease participants; HC=Healthy Controls.
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Table 9
Aim 2: Means and Standard Deviations for the Poser Group by Gender by Time by Emotion
Interaction for EI (p = .103)
Group
LSVT
Emotion
Angry
Happy
Sad
Time
Pre
Post
Pre
Post
Pre
Post
Men
1.83 (.29)
2.16 (.28)
1.88 (.30)
2.17 (.27)
1.84 (.34)
1.95 (.27)
Women
2.29 (.64)
2.33 (.61)
2.39 (.66)
2.67 (.59)
1.85 (.75)
3.28 (.59)
Group
Emotion
Time
Men
Women
Group
Emotion
Time
Men
Women
Group
Emotion
Time
Men
Women

Angry
Pre
1.93 (.31)
3.02 (.39)

ARTIC
Happy
Post
1.96 (.30)
2.83 (.37)

Pre
1.97 (.32)
3.24 (.40)
UPD
Happy

Angry
Pre
2.25 (.29)
3.70 (.50)

Post
2.44 (.28)
2.96 (.47)

Pre
2.34 (.31)
4.29 (.52)

Post
2.39 (.29)
3.28 (.38)

Pre
2.44 (.32)
3.23 (.41)

Sad
Pre
1.62 (.36)
3.25 (.45)

Post
1.83 (.29)
2.53 (.36)

Sad
Post
2.43 (.27)
3.34 (.46)

HC
Happy

Angry
Pre
2.60 (.31)
3.06 (.40)

Post
2.15 (.29)
3.07 (.35)

Pre
2.07 (.34)
3.55 (.58)

Post
2.07 (.27)
3.50 (.46)

Sad
Post
2.49 (.28)
3.23 (.37)

Pre
2.46 (.36)
3.01 (.46)

Post
2.09 (.29)
3.19 (.37)

Note. LSVT=Lee Silverman Voice Treatment; ARTIC=Articulation Treatment; UPD=Untreated Parkinson’s
disease; All PD=All Parkinson’s disease participants; HC=Healthy Controls.
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Table 10
Correlations between Demographic, Clinical, Cognitive, and Affective Variables and Face Variables for
LSVT
FM
FM
EF
EF
EV
EV
EI
EI
SE
SE
Neg.
Pos.
Neg.
Pos.
Neg.
Pos.
Neg. Pos.
Neg.
Pos.
Gender

.720**

.708**

.449

.
551*

.
553*

.614*

.409

.372

.246

.284

Age

.033

-.044

-.019

-.090

-.022

-.075

-.009

-.109

-.028

-.042

Education

.024

.127

.552†

.426

.285

.297

.269

.227

.192

.345

BDI-II

.670*

.628*

.364

.546†

.572†

.599*

.458

.486

.416

.366

MMSE

-.539†

-.513†

-.32

-.469

-.540

-.473

-.418

-.403

-.507†

-.606*

H&Y
Stage

.421

.379

.312

.403

.397

.363

.345

.294

.441

.494

SMS

-.443

-.470

-.259

-.311

-.399

-.470

.326

-.381

-.129

.043

Illness
Duration

.553†

.625*

.044

.204

.322

.280

.188

.204

.090

.106

Note.
1
FM = Facial Mobility; EF = Emotional Frequency; EV = Emotional Variability; EI = Emotional Intensity; SE = Social
Engagement.
2
SMS = Side of Initial Motor Onset; Neg. = Negative Emotions (Sad & Angry); Pos. = Positive Emotion (Happy)
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Table 11
Multiple Regression Analyses: LSVT Change Scores and Demographic, Clinical, Cognitive,
& Affective Variables

Positive Emotion
2

Negative Emotion

R

p-value

R2

p-value

FM

.27

.648

.05

.981

EF

.42

.367

.18

.819

EV

.25

.216

.12

.909

EI

.28

.637

.06

.972

SE

,66

.077

.15

.858

Note. FM = Facial Mobility; EF = Emotional Frequency; EV = Emotional Variability; EI = Emotional
Intensity; SE = Social Engagement.
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Table 12
Multiple Regression Results for SE Positive Emotion (R2 = .66, p = .077)

Variable

β

t

p-value

Gender

-.565

-2.42

.046

MMSE

.529

1.93

.094

Illness Duration

.053

0.19

.858

BDI-II

.659

2.37

.050

Note. SE = Social Engagement
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Figure 1
Poser Group x Gender Interaction for Facial Mobility (p=.092)
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Figure 2
Group x Emotion Interaction for Emotional Variability (p=.040): Group Comparisons
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74

Figure 3
Group x Emotion Interaction for Social Engagement (p=.057): Group Comparisons
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Figure 4
Group x Emotion Interaction for Emotional Variability (p=.040): Emotion Comparisons
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Figure 5
Group x Emotion Interaction for Social Engagement (p=.057): Emotion Comparisons
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Figure 6
Gender x Emotion Interaction for Facial Mobility (p=.009): Gender Comparisons
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Figure 7
Gender x Emotion Interaction for Social Engagement (p=.017): Gender Comparisons
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Figure 8
Gender x Emotion Interaction for Facial Mobility (p=.009): Emotion Comparisons
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Figure 9
Gender x Emotion Interaction for Social Engagement (p=.017): Emotion Comparisons
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Figure 10
Poser Group x Time Interaction for Facial Mobility (p=.020)
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Figure 11
Poser Group x Time Interaction for Emotional Frequency (p=.043)
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Figure 12
Poser Group x Time Interaction for Emotional Intensity (p=.029)
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Figure 13
Poser Group x Time Interaction for Emotional Variability (p=.082)
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Figure 14
Poser Group x Gender x Time for Facial Mobility (p=.046)
5
4.5

Facial Rating

*

†

4
3.5
3
2.5

*

2
1.5
1
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post
Men

Women
LSVT

Men

Women
ARTIC

Men

Women
UPD

Note. **p≤.01; *p≤.05; †p≤.10

86

Men

Women
HC

Figure 15
Poser Group x Gender x Time for Emotional Variability (p=.023)
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Figure 16
Poser Group x Gender x Time for Emotional Intensity (p=.012)
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